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Abstract 
Salicylanilides are an important class of aromatic compounds with a wide range of 
pharmacological activities, such as antibacterial, antifungal and anti-inflammatory, among 
others. Furthermore; several studies reported their potent antimycobacterial effect. Their 
activity results from multiple mechanisms. They are therefore interesting compounds for 
medicinal chemists. As phenolic-containing drugs, we hypothesised that a prodrug approach 
will make possible the improvement of the pharmaceutical, pharmacokinetic and/or 
pharmacodynamic properties of salicylanilides. 
This thesis describes the development of new potential antimycobacterial active agents based 
on this group that have shown interesting antimycobacterial activity against Mycobacterium 
tuberculosis, and some atypical strains. 
As the starting point for our research, the different strategies used in order to overcome the 
limited bioavailability of phenolic drugs were reviewed. Then new potentially antibacterial 
active prodrugs of salicylanilides, particularly N-benzyloxycarbonyl-ester and alkyl-
carbamate derivatives of salicylanilide, active against M. tbc., MDR-TB strains or non-TB 
strains such as M. avium and M. kansasii, were prepared. Finally the physicochemical and 
pharmacokinetic properties of the most active synthesised compounds were explored. For the 
esterification, N-protected, mainly N-benzyloxycarbonyl amino acids were used. The 
synthesised esters result to have comparable activity to the starting salicylanilides. In the 
course of our research, we have also investigated and elucidated the mechanism for the 
unexpected formation of novel seven-membered ring benzoxazepines and 2-hydroxy-N-(1-
(oxo-(phenylamino)-alkan-2-yl)benzamides. All the studied alkyl-carbamate derivatives of 
salicylanilide exhibited higher activity against M. tbc., M. kansasii and M. avium compared to 
the starting salicylanilide and promising activity against five MDR-TB strains, with MIC 
values between 0.5-2 mol/L. Furthermore, as prodrug forms, they seem to fulfil better 
conditions than the corresponding synthesised esters, due to the increment of the half time of 
hydrolysis to several hours and to the stability in acidic environment. 
All these results have been submitted, accepted or already published in several impact-
scientific journals and presented in different national and international symposia.
  
 
 
Abstrakt 
Salicylanilidy jsou důležitou skupinou aromatických sloučenin, které vykazují široké 
spektrum různých farmakologických aktivit, především antibakteriální, antifungální a 
protizánětlivý efekt. Několik studií presentuje rovněž jejich významný antimykobakteriální 
účinek a mechanismus působení, lišící se od ostatních antimykobakteriálně aktivních 
sloučenin. Vzhledem k fenolickému charakteru těchto sloučenin lze předpokládat, že tvorba 
vhodné formy proléčiva zlepší jejich farmakochemické, farmakokinetické a 
farmakodynamické vlastnosti. 
Tato práce se zabývá vývojem nových forem proléčiv antimykobakteriálně aktivních 
sloučenin na bázi salicylanilidů, které vykazují srovnatelné aktivity s běžnými 
antituberkulotiky vůči Mycobacterium tuberculosis, ale také vůči některým netuberkulózním 
kmenům jako je M. avium a M. kansasii, popř. kmenům, rezistentním na běžná 
antituberkulotika, kde jsou dokonce účinnější. 
Na základě literární rešerše, která byla podkladem pro sepsání přehledného článku o literárně 
dostupných modifikacích léčiv, majících fenolickou hydroxyskupinu, byla cílem této práce 
příprava vhodné formy proléčiv antimykobakteriálně aktivních salicylanilidů, které by 
překonaly limitovanou biodostupnost a zlepšily fyzikálně chemické a farmakokinecké 
vlastnosti těchto fenolických sloučenin formou esterů a karbamátů. Pro esterifikaci byly 
použity N-chráněné, nejčastěji N-benzyloxykarbonylové aminokyseliny. Jejich estery se 
ukázaly být srovnatelně aktivní s výchozími salicylanilidy. Během těchto reakcí došlo ke 
tvorbě sedmičlenných benzoxazepindionů a 2-hydroxy-N-(1-(oxo-(fenylamino)-alkan-2-
yl)benzamidů, vzniklých nečekaným přesmykem. Na základě experimentálních studií a díky 
izolaci a charakterizaci pětičlenného imidazolinonového meziproduktu byl potvrzen jeden 
z navržených mechanismů přesmyku. Salicylanilidové karbamáty vykázaly dokonce vyšší 
antimykobakteriální aktivitu oproti výchozím salicylanilidům. Působí rovněž na 5 
rezistentních kmenů v MIC 0,5-2 mol/L a jako formy proléčiv se zdají být daleko vhodnější 
ve srovnání s estery, díky poločasu hydrolýzy, který se pohybuje v rozmezí několika hodin. 
Všechny presentované výsledky jsou předmětem několika publikovaných sděleních v 
mezinárodních impaktovaných časopisech, popř. byly zaslány či jsou přijaty k publikaci a 
vyjdou v nejbližší době. 
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1. Introduction. 
 
1.1. Tuberculosis. 
Tuberculosis (TB) is an infectious bacterial disease caused by Mycobacterium tuberculosis 
(M. tbc.), which most commonly affects the lungs but can also affect the central nervous 
system, the lymphatic system, the circulatory system, the genitourinary system, the 
gastrointestinal system, bones, joints, and even the skin.  
1.1.1. World TB incidence. 
Nearly 2 billion people are presently infected with M. tbc. Not everyone who is infected 
develops the active form; an asymptomatic latent form of TB is insidious. However, one in 
ten latent infectious will progress to the active TB disease which, if left untreated, will kill 
more than half of its victims. Every year around 9 million people develop the active and 
contagious pulmonary TB and 20% of these victims die of their infection, mostly in 
developing countries 1,2. WHO estimates than 9.27 million new cases of TB occurred in 
2007 (139 per 100,000 population), more than 4% of all the world-wide TB patients are 
resistant to at least one of the current first line drugs 3. The recent worldwide emergence of 
drug-resistant TB, caused by poorly managed TB treatment is a growing problem of serious 
matter in many countries around the world, especially the increase of multidrug-resistant TB 
(MDR-TB) 4,5 and, most recently, extensively drug-resistant TB (XDR-TB) 6. Every year 
almost 500,000 people are infected with MDR-TB and there are estimated 40,000 new cases 
of XDR-TB annually 7,8. TB in co-occurrence with the spread of human immunodeficiency 
virus (HIV) infection 9 belongs amongst the most serious worldwide health threats. Among 
the 9.27 million incident cases of TB in 2007, an estimated 1.37 million (14.8%) were HIV-
positive. Therefore, effective new drugs 10 and strategies 11 to treat the TB bacilli as well 
as its resistance pattern are an urgent demanding task. 
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1.1.2. TB treatment. 
Modern TB chemotherapy started with the discovery of streptomycin (STM) in 1944. Two 
years later, para-amino-salicylic acid (PAS) was discovered. In 1952, two important front-
line TB drugs, isoniazid (INH) and pyrazinamide (PZA) were introduced in the clinical 
treatment of TB. Ethambutol (EMB), a synthetic anti-TB, was discovered in 1961, followed 
by the introduction of rifampin (RIF) in 1967; both are effective TB drugs. An important 
observation in the early days of TB chemotherapy was that the use of a combination of two or 
more drugs greatly reduced emergence of drug resistance. Current treatment is made up of a 
cocktail of the first-line drugs (INH, RIF, PZA and EMB) for a period of six months 12 . 
The principles of treatment for MDR-TB and for XDR-TB are the same. The main difference 
is that XDR-TB is associated with a much higher mortality rate than MDR-TB, because of a 
reduced number of effective treatment options 13. Treatment courses are a minimum of 18 
months and may last years, second-line drugs are used, such as PAS, kanamycin, 
fluoroquinolones, capreomycin, ethionamide and cycloserine. These drugs are generally either 
less effective or more toxic, with serious side effects 14. 
The drugs currently used as anti-TB agents and new drug candidates and therapeutic targets 
for TB chemotherapy have been extensively described. See for example, Zhang et al. 15,16, 
Protopopova et al. 17. 
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2. Aim of the thesis. 
Clearly there is a need for antibacterial agents with novel mechanism of action and thus 
salicylanilides (SAL) are promising candidates. The overall aim of this thesis was to 
investigate the most suitable prodrug forms based on this group  that have shown interesting 
antimycobacterial activity against M. tbc. and some atypical strains, where INH is non-active. 
As a phenolic-containing drug, SAL are subjected to extensive first pass metabolism and, 
non-lipophilic character results in poor bio-membrane passage. Alternatively, the presence of 
a phenolic group should bring the possibility of a prodrug approach making possible the 
improvement of the pharmaceutical, pharmacokinetic and/or pharmacodynamic properties of 
the SAL. As the starting point for our research, the different strategies used in order to 
overcome the limited bioavailability of phenolic drugs were reviewed. Then, new potentially 
antibacterial active prodrugs of SAL, particularly active against M. tbc., MDR-TB strains or 
non-TB strains such as M. avium and M. kansasii were prepared to finally explore their 
physicochemical and pharmacokinetic properties.  
 
The specific objectives of this study were: 
 Literary review of prodrug design of phenolic-containing drugs (Paper I). 
 Development methods for the synthesis of amino acid esters of salicylanilides and 
biological evaluation of the synthesized compounds (Paper II, III). 
 Development methods for the synthesis of alkyl carbamate esters of salicylanilides and 
biological evaluation of the synthesized compounds (Paper V). 
 Study of the unexpected formation of novel benzoxazepine seven-membered rings 
(Paper IV).  
 Study of the rearrangement that leads to 2-Hydroxy-N-(1-(oxo-(phenylamino)-alkan-
2-yl)benzamides (Paper VI). 
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3. Prodrug design of phenolic drugs (Paper I). 
The phenolic functional group is one of the most common functional groups found in drug 
molecules such as narcotic agonists and antagonists, estrogens, neurotransmitters, anticancer 
agents or antibacterial agents, among others. However, phenolic drugs usually present limited 
bioavailability and thus limited effectivity. 
Due to their poor delivery characteristics caused by their metabolic instability, they are often 
subjected to extensive first pass metabolism and in general, non-lipophilic character results in 
poor bio-membrane passage. Solubility limitations have been also frequently encountered in 
the development of commercial phenolic drugs. Alternatively, the presence of phenolic 
groups brings the possibility of prodrug approach which can result in effective, safe and 
efficient delivery of the parent drug to the systemic circulation and to the desire site of action. 
Several strategies have been used in order to overcome the limited bioavailability of phenolic 
drugs. Examples of ester, sulphate, carbamate, phosphate and ether prodrugs as well as the 
limitations of these prodrug strategies are reviewed in this chapter. 
3.1. Introduction. 
The principal mechanism used by the human body to eliminate low molecular weight 
environmental pollutants is the use of non-specific enzymes, which transform the extraneous 
compounds into polar molecules, excreted by natural bodily processes. Despite the fact that 
this mechanism can be highly preferable to rid the body of xenobiotics, it can represent a 
problem when the foreign agent is a drug that should enter and be retained in the body enough 
time to be effective. The enzymatic biotransformation of drugs is known as drug metabolism. 
When a drug is taken orally, it is usually absorbed through the membrane of the small 
intestine or from the stomach. Then it is carried by the bloodstream to the liver where it is 
often first metabolized. The complete deactivation of the drug may result if metabolism by 
liver enzymes occurs before the drug reaches the systemic circulation (presystemic or first-
pass effect). Two undesirable effects of drug metabolism are, on one hand the larger or 
multiple doses of the drug that will be required to accomplish the desired effect and on the 
other hand the possible toxic metabolites originated in these processes, even though the parent 
drug will be not toxic. The first-pass effect can be avoided either changing the route of drug 
administration or via structural modifications approaches in drug design. Once the drug has 
reached its site of action and achieved the desired objective, should be metabolized and 
eliminated at a reasonable rate, otherwise, it can stay in the body and produce a longer effect 
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than desired or accumulate and became toxic for the cells 18. Drug metabolism reactions are 
divided into two general categories, named phase I and phase II reactions. Phase I 
transformations involve reactions that introduce or unmask a functional group, such as 
oxygenation or hydrolysis. Phase II transformations mostly generate highly polar derivatives, 
such as glucuronides and sulphate esters, for excretion in the urine.  
Phenolic drugs are often subjected to phase II metabolism 18,19. This phase II modification 
is responsible for deactivation of drugs, can change their physicochemical properties and 
produce water-soluble metabolites that are excreted in the urine or bile. Therefore, phenolic 
drugs show low bioavailability after oral administration and thus limited effectivity. The 
inactivation of these drugs in the gut and/or liver is due to glucuronidation, sulphatation or 
methylation. Glucuronic acid conjugation is the most common mammalian conjugation 
pathway. Four general classes of glucuronides have been established, the O-, N-, S- and C- 
glucuronides. Sulphate conjugation occurs less frequently than glucuronidation. The main 
substrates involved in sulphatation are phenols but alcohols, amines and to a much lesser 
extent, thiols are also sulphated. It tends to predominate at low doses, when there is less to 
diffuse into membranes and with smaller, less lipid-soluble molecules. Methyl conjugation is 
relatively minor conjugation pathway in drug metabolism; in general, xenobiotics that 
undergo methylation do share marked structural similarities to the endogenous substrates that 
are methylated. 
Alternatively, the presence of phenolic groups brings the possibility of prodrug approach 
20,21 making possible the improvement of the pharmaceutical, pharmacokinetic and/or 
pharmacodynamic properties of the parent drug. 
One of the most important pharmacokinetic characteristic of a new drug candidate is its oral 
bioavailability 22,23. As it was mentioned above, phenolic drugs have often limited 
systemic bioavailability due to extensive presystemic metabolism. In this context, one strategy 
would be to administrate the drug orally as a prodrug able to pass intact through the potential 
sites of metabolism, converting to the parent drug in an organ other than the intestine or the 
liver. 
Another prodrug strategy would be to temporally mask polar groups resulting in an increased 
lipophilic molecule, which would promote membrane permeability. Esterification of the 
hydroxyl group(s) has been one of the preferred prodrug strategies for this purpose. As a case 
in point, consider lipophilic prodrugs designed for intestinal lymphatic transport 24, 
prodrugs for improved the central nervous system (CNS) delivery 25 or, among other 
promising nonoral, nonparentenal routes, prodrugs for nasal delivery 26. 
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Cancer chemotherapy is closely associated with serious side effects due to the high toxicity of 
the used drugs. In order to minimize systemic toxicity of the parent drug, a number of 
prodrugs of phenolic group-containing have been targeted toward molecular receptors on 
tumour cells for in situ activation. The different prodrugs strategies in cancer therapy have 
been examined extensively in the literature 27,28,29,30,31.  
Herein, we offer a summary of the various prodrug strategies design to modify the phenolic 
group, focusing on the physicochemical properties and pharmacokinetics of the representative 
compounds, showing the biochemical pathways involved in prodrug activation and illustrating 
these with relevant examples. 
3.2. Ester Prodrugs of Phenols. 
The aim of the ester prodrug approach is to mask polar ionisable groups (phenolic, hydroxyl 
or carboxylic group) within a molecule, enhancing the aqueous solubility and stability of the 
compound 32 to provide a sustained-release derivative of the parent drug or increasing its 
lipophilicity 33 to promote permeability and oral absorption. When the ester bond of the 
prodrug is cleaved, the active drug is released. This cleavage usually occurs through 
hydrolysis or oxidation 34. The hydrolysis of the prodrug is usually catalyzed by different 
esterases, including carboxylesterase, acetylcholinesterase, butyrylcholinesterase, 
paraoxonase and arylesterase. The oxidation of ester-based prodrugs is catalyzed by 
cytochrome P450s (Scheme 1). 
 
R1 O
O
H2O
Pathway A
R1 OH
O
OH
Pathway B
R1 O
O
Drug
OH
Drug Drug
R1 OH
O
HDrug
O
Drug OH
O
 
Scheme 1. Pathways for ester bond cleavage. Pathway A: Esterases or proteins (HAS, 
carboxypeptidase A, aldehyde dehydrogenase, carbonic anhydrase B and C, lipases) having 
esterase activity. Pathway B: Cytochrome P450s 34. 
 
 
  
7 
 
As an alternative approach, the parent drug can be regenerated through non-enzymatic 
pathways, particularly via cyclization-elimination strategies 35,36. Begtrup and co-workers 
37 developed hemiesters of aliphatic dicarboxylic acids as cyclization-activated prodrugs of 
phenols that were released after the attack of the carboxylate on the ester bond (Scheme 2). 
 
 
R
O
O
COOH
+H
R
O
O
COO
+H
R
OH
OO
O
-H
 
Scheme 2. Carboxylate nucleophiles in the intramolecular activation of phenol prodrugs 36. 
 
Another example of non-enzymatic pathway was presented by Gomes and co-workers 38, 
they have considered that dipeptides might play a crucial role as carriers for hydroxyl-
containing drugs. Dipeptide esters and amides can deliver the parent drug through an 
intramolecular cyclization to form the corresponding piperazine-2,5-diones (DKP) (Scheme 
3) 35,36.  
 
H2N
R1 H
N
O R2
O
O
Drug
NH
O
O
R1
R2
Drug
OH
 
Scheme 3. Prodrug intramolecular activation via DKP formation 36. 
 
The bioconversion to the active drug determines its utility as a prodrug. The rate of 
biotransformation is particularly important due to its role for the onset, duration and intensity 
of the drug action. Many factors may contribute to the prodrug conversion rate as genetic 
differences, environmental effects and disease states. Although some of these factors, such as 
structural aspects of prodrugs, can be optimized in drug discovery, others are intrinsically 
related to individuals, adding complexity of the attempt to predict drug stability. 
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After oral administration, morphine (1) (Figure 1) is almost completely absorbed from the 
gastro-intestinal tract, however, due to extensive first pass metabolism the systemic 
bioavailability is low and variable (19-47%) 39. Following parenteral administration side-
effects may occur as a consequence of high pick plasma levels. Bioavailability of morphine 
after buccal and sublingual administration is as well quite limited, apparently cause of its poor 
lipophilicity and polar properties at physiological pH. A prodrug approach to enhance 
penetration of morphine through the buccal mucosa was achieved by esterification of its 3-
phenolic group 40. All the morphine esters studied underwent enzymatic hydrolysis, the 
acetoyl prodrug (2) (Figure 1) was found to be the most stable derivative in both plasma and 
saliva. The ester prodrugs tested were able to permeate porcine buccal mucosa, whereas the 
parent drug 1 was not at any measurable extent. Even if permeation of 1 can be markedly 
improved by using ester prodrugs with higher lipophilicity, the enzymatic stability of the 
prodrugs in saliva do also play an important role for the overall improvement in absorption 
properties. Similar approach has been used to improve transdermal penetration where various 
alkyl esters formed at the 3- and/or 6-hydroxy group in 1 were prepared, showing higher 
penetrating capacity due to higher water and lipid solubility than the parent drug 1 41. The 
hexanoyl prodrugs (3 and 4) (Figure 1) delivered only 1 while propionyl prodrug (5) 
delivered 50:50 intact prodrug:morphine. This correlates with other reports 42 where it is 
demonstrated that the medium alkyl chain length homologues are more completely 
hydrolyzed to the parent drug than the shorter or longer alkyl chain ones. 
 
 
NH
HO
O
HO
1
NH
HO
O
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NH
O
O
O
3
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4
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O
O
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Figure 1. Morphine (1) and its ester prodrugs (2, 3, 4, 5). 
 
Nalbuphine (6) (Figure 2) is a synthetic opioid used commercially as an analgesic that 
present incomplete oral bioavailability in animals and humans attributable to extensive 
presystemic metabolism via conjugation on the phenolic hydroxyl group. Two prodrugs were 
presented 43 in preclinical studies as candidates with improved oral bioavailability, the 
acetylsalicylate (7) and anthranilate (8) esters (Figure 2). The increment of bioavailability 
after oral administration in dogs was demonstrated, from 5-7% for 6 to approximately17-24% 
for 7 or 50% for 8. Furthermore, the plasma concentrations of conjugated 6 were reduced after 
dosing with the prodrugs, elucidating that first-pass metabolism was reduced. 
 
HO
O
HO
N
OH
6
O
O
HO
N
OH
7
O
COCOCH3
O
O
HO
N
OH
8
O
NH2
 
Figure 2. Nalbuphine (6) and its ester prodrugs (7, 8). 
 
Contrary to other typical opiates such as 1 (Figure 1), meptazinol (9) (Figure 3) accompanies 
less respiratory depression and addictive potential. Nevertheless, 9 displayed poor oral 
bioavailability (8.96%) 44 because of serious first-pass effect in liver similar to the opiate 
described above. Qiu and co-workers 45 reported the synthesis of three benzoyl esters of 9 
with the aim to protect this drug from enzyme metabolism and enhance hydrophobicity as 
well as to improve its pharmacokinetic properties. 2-Amino-6-methylbenzoyl prodrug (10) 
(Figure 3) showed significant increase in looped duodenum, jenunum and colon absorption 
than 9 which correlated well with its enhanced bioavailability. Notice here that the carbonyl 
group is surrounded by both the 2´-amino and the 6´-methyl group which could thusly protect 
the ester bond from hydrolysis. As part of a continuing effort to develop novel 9 prodrugs, a 
coumarin-based esterase-sensitive prodrug approach was reported 46. Its application for the 
preparation of prodrugs of amines and cyclic prodrugs of peptides has been discussed 
extensively in the literature 47,48,49,50,51.The major advantage of the prodrug system is 
that hydrolysate coumarin seems to be relatively non-toxic. The propionyloxy group-
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substituted phenyl propenoic acid was chosen as carrier molecule. 3-(2-(prop-1-en-2-
ylperoxy)phenyl)acryloyl prodrug (11) (Figure 3) showed a superior oral bioavailability to 
the earlier reported benzoyl esters 45. These results encourage the use of coumaring-based 
esterase-sensitive system as a prodrug template for other drug molecules besides 9. 
 
OHN
9
ON
10
O NH2
ON
11
O OOCCH2CH3
 
Figure 3. Meptazinol (9) and its ester prodrugs (10, 11). 
 
Propofol (12) (Figure 4) is an intravenous (i.v.) agent with very low aqueous solubility. At 
present, the anaesthetic agent is formulated as 1% w/v of oil/water emulsion of soya bean oil, 
glycerol and purified egg phosphatide (Diprivan

). Unfortunately, these emulsions present 
several limitations including poor physical stability, potential for embolism and pain on 
injection 52. In order to increase the aqueous solubility and to reduce side effects as well as 
to prolong the drug action, several prodrug strategies have been described. N,N-disubstituted-
α-amino acid esters were synthesized 53 and their physicochemical properties were studied. 
Among them, the pyrrolidinoacetyl ester (13) (Figure 4) showed half maximal inhibitory 
concentration (IC50) value comparable to 12 as well as the highest solubility in aqueous 
solution, however, after the study of enzymatic stability, it was found that these candidates 
can not be considered as prodrugs since they are not readily converted to the parent drug in 
physiological conditions. In a later study, cyclic amino acid esters of 12 were synthesized 
54. L-proline ester of propofol (14) (Figure 4) was found to protect animals against 
pentylentetrazol-convulsions and to induce in a shorter time an anaesthetic action with 
comparable duration as marketed emulsion Diprivan

. Its high solubility and stability in water 
at physiological pH would aloud freeze-dried formulations to be used for parenteral 
administration. Its susceptibility to enzymatic cleavage by esters hydrolases in plasma and 
liver should afford a rapid conversion to the parent drug. Finally, the comparable IC50 values 
with 12 showed that 14 is a propofol prodrug candidate for developing formulations useful for 
i.v. administration. 
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Figure 4. Propofol (12) and its ester prodrugs (13, 14). 
 
Application of peptides as clinically useful drugs represent an important task due to their poor 
delivery characteristics caused by their metabolic instability and in general a non-lipophilic 
character resulting in poor membrane absorption. This leads to bioavailabilities less than 1-
2% 55. Clinical development of drug candidates that are peptide based has therefore been 
restricted. In the recent past, the prodrug approach has been used in order to improve 
bioavailability of peptides 56,57,58. With this purpose, study of ester prodrugs of the 
tyrosine phenolic group of a Leu-enkephalin analogue (15) (Figure 5) was reported 59. This 
analogue already shows favourable properties in comparison with Leu-enkephalin. The 
substitution of Gly
2
 with D-Ala
2
 significantly decreases the enzymatic hydrolysis of the Tyr
1
-
Gly
2
. Amidation of the C-terminal offers protection against degradation by carboxypeptidases 
60,61. The most favourable prodrug candidate in this study was the pivaloyl ester of Leu-
enkephalin analogue (16) (Figure 5), showing 18 times higher transport compare to the 
analogue itself, what suggests that more sterically hindered prodrugs improve stability and 
thereby penetration through the intestine and blood-brain barrier (BBB). 
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Figure 5. Leu-enkephalin analogue (15) and its ester prodrug (16). 
 
The extensive first-pass metabolism of paracetamol (17) “Fig. (6)” can lead to serious hepatic 
and renal toxic effects 62. Esterification of 17 with some non-steroidal anti-inflammatory 
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carboxylic acids was reported as mutual prodrug in order to prevent the severe hepatotoxicity 
of the drug at high doses 63. According to this study, 2-(4-isobutylphenyl)propanoyl ester of 
paracetamol (18) (Figure 6) was found to be more bioavailable orally than the parent drugs in 
physical mixture due to improved lipophilicity; furthermore, ulcerogenic liability was reduced 
providing the corresponding improvement in the therapeutic index (TI) of the parent drugs. 
In a recent study in prodrug design, dipeptide esters of 17 were reported 38. In contrast to 
the previous study, where mutual prodrugs were found to be susceptible to enzymatic 
hydrolysis; the delivery of the parent drug is, in this case, through enzyme-independent 
processes such as an intramolecular cyclization to form the corresponding DKP 64. 
Compounds 19 (Phe-Gly-trifluoroacetate), 20 (Gly-Val-trifluoraoacetate), 21 (Gly-Phe-
trifluoroacetate) (Figure 6) were proved to efficiently reduce hepatotoxicity of 17. However, 
the selection of the dipeptide carrier must consider the potential side effects of the 
corresponding DKP formed during the cyclization. 
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Figure 6. Paracetamol (17) and its ester prodrugs (18, 19, 20, 21). 
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3.3. Phosphate Ester Prodrugs of Phenols 
Phosphate ester prodrug approach has overcome numerous drug delivery problems of 
sparingly water soluble potential drugs. The phosphate moiety can be directly attached to the 
parent drug to form a phosphomonoester which undergoes an alkaline phosphatase-catalyzed 
bioconversion in vivo to release the parent phenol drug and inorganic phosphate, or via a 
chemical linker such a oxymethyl spacers, usually used to increase the space around the 
enzymatically cleavage bond 65. These prodrugs undergo rapid spontaneous chemical 
hydrolysis most notably by endothelial cell surface alkaline phosphatases liberating the parent 
drug, phosphate and formaldehyde (Scheme 4). This enzyme is responsible for removing 
phosphate groups from many types of molecules, including nucleotides, proteins, and 
alkaloids and cleaves the phosphomonoester at the phosphorous-oxygen bond with high 
catalytic efficiency 66. 
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Scheme 4. Pathway for phosphate ester bond cleavage. 
 
We have previously shown how the anaesthetic drug 12 (Figure 4) has lead to the 
development of more water-soluble prodrugs for i.v. administration 53,54. For this purpose, 
at least three phosphate prodrugs of 12 have been described in the literature. Firstly, one with 
the phosphate group attached directly to the phenolic functionality of 12, named PP (22) 
(Figure 7) 67, well defined water-soluble prodrug of 12 that is enzymatically converted to 
the parent drug and non-toxic inorganic phosphate. In contrast with 12, 22 is formulated on 
water as a sodium salt (3.1% wt/vol; pH 7.4) and sterilized by filtration (0.2 m) and then is 
ready for i.v. administration. Although the 22 hypnotic dose (HD50) was found to be around 
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10 times larger than the HD50 values reported for 12, the PP lethal dose (LD50) was as well 
bigger in mice, rats and pigs; this implies lower hypnotic activity and lower toxicity so it 
would be possible to applied larger doses of 22 to achieve the same level of sedation as with 
12. The second prodrug of 12 presented was one with an oxymethyl spacer between the parent 
drug and the phosphate promoiety, named GPI 15715 (Aquavan

) (23) (Figure 7) 68. The 
enzymatic hydrolysis of 23 is faster than that of 22, however 22 does not liberate the toxic 
formaldehyde, which in addition to its toxicity may alter homeostasis within cells. Finally, it 
was presented one with an ethyl dioxy-spacer between 12 and the phosphate promoiety that 
liberates the much less toxic compound, acetaldehyde, from the prodrug structure 69. Ethyl 
dioxy phosphate of propofol (24) (Figure 7) greatly enhanced the aqueous solubility of 12, 
being sufficient for i.v. administration. Furthermore, 24 was bio-converted to 12 as efficiently 
as 23 and much faster and more effective than 22. Nevertheless, larger doses would be needed 
to achieve complete sedation. This effect is similar to that reported earlier in previous cases. 
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Figure 7. Propofol phosphate ester prodrugs (22, 23, 24). 
 
Cobretastatins are natural compounds isolated from the Combretum caffrum willow tree in 
South Africa. One of them CA-4 (25) (Figure 8), named as tubulin-binding agent, can induce 
vascular damage and subsequent hemorrhagic necrosis in tumours. This agent causes the 
destabilization of the tubulin polymers of the cytoskeleton 70. It was shown that a more 
soluble prodrug of 25, CA-4-P (26) (Figure 8) 71,72, which can now be delivered 
systematically, can cause vascular shut-down in the murine adenocarcinoma NT and the 
human breast carcinoma xenografts MDA-MB-231. This compound is cleaved to the active 
25 by endogenous non specific phosphatases and its effects can be achieved using relatively 
non-toxic doses. Further investigations showed that the vascular-damaging effect of 26 were 
larger in tumour tissue than in any of the normal tissues investigated 73. 26 is currently in 
Phase I/II clinical trials. 
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Figure 8. Cobretastatin CA-4 (25) and its phosphate ester prodrug (26). 
 
Etoposide (27) (Figure 9) is a semi-synthetic derivative of podophyllotoxin that is given as a 
treatment for some kinds of cancers. Possessing potent antineoplastic properties, binds to and 
inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the 
accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and 
transcription and apoptotic cell death. The equilibrium aqueous solubility of 27 is low, 0.15-
0.7 mg/mL, making necessary the use of organic solvents and big volumes of saline for i.v. 
administration, therefore, a phosphate prodrug of 27 was developed 74. Etoposide phosphate 
(Etopophos

) (28) (Figure 9) is water soluble (20mg/mL) and is available for i.v. infusion as 
a sterile lyophile in single-dose vials containing 28 equivalent to 100 mg of 27, 32.7mg 
sodium citrate USP, and 300 mg dextran 40. 28 quantitatively converts to the parent drug after 
i.v administration in humans and has equivalent TI and toxicity than 27 75,76. 28 is actually 
used for the treatment of small cell lung cancer and testicular carcinoma. 
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Figure 9. Etoposide (27) and its phosphate ester prodrug (28). 
 
The fluoroquinolone PA2789 (29) (Figure 10) is an effective antibacterial agent for lung 
infections; however, it was later determined to have poor oral bioavailability. The low oral 
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bioavailability of 29 precludes high systemic levels of 29 during aerosol delivery, confining 
the drug to pulmonary tissue. Although this property appears to be desirable, as the goal is to 
deliver active compound to the lungs and minimize systemic exposure from any compound 
entering the stomach during inhalation, poor water solubility of this drug restrains its use as 
an aerosol. With the aim of improving the water solubility of 29, the prodrug PA2808 (30) 
(Figure 10) which contains a phosphate group attached to the phenolic group at the N-1 
position, was published 77. 30 presented increased solubility achieve at pHs that are 
physiologically acceptable (pH range 4.5-8.7, out of this range inhaled aerosols can cause 
coughing or bronchoconstriction) 78, displayed excellent activity against the organism 
tested and was converted into 29 after phosphate cleavage by alkaline phosphatase. 
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Figure 10. Fluoroquinolone PA2789 (29) and its phosphate ester prodrug (30). 
 
DP-TAT-59 (31) (Figure 11) is a practically insoluble analogue of tamoxifen, an antagonist 
of the estrogen receptor in breast tissue, therefore used in the treatment of breast cancer. In 
order to increase the solubility of 31, a phosphate prodrug strategy was developed. 
Miproxifene phosphate (TAT-59) (32) (Figure 11) was synthesized 79,80 and actually is in 
phase II-III trials. Surprisingly 32 showed unusual low solubility comparing to most 
phosphate esters freely soluble in water 81,82. Despite the relatively low solubility of 32, its 
solubility and dissolution rate were much higher than those of the parent drug, making 
succeed the prodrug approach. The dephosphorylation in vivo of 32 was rather quick as it was 
shown in pharmacokinetics studies. The bioavailability of 31 after oral 32 dosing was 28.8% 
in rats and 23.8% in dogs. Furthermore, no intact prodrug was detected in plasma of either 
species. However, no bioavailability data have been published for humans. 
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Figure 11. Tamoxifen analogue DP-TAT-59 (31) and its phosphate prodrug (32). 
 
Entacapone (Comtan

) (33) (Figure 12) is used in the treatment of Parkinson’s disease (PD) 
and works as a catechol-O-methyl transferase inhibitor. It is used as a support in the 
levodopa/carbidopa (Sinemet

) therapy 83. Common treatment of PD involves oral 
administration of a combination of levodopa, a precursor of dopamine that can cross the BBB 
and carbidopa, an inhibitor of dopa decarboxylase, which inhibits decarboxylation of 
levodopa in the periphery. 33 presents a low oral bioavailability (~25-35%). Although the 
factors contributing to its poor bioavailability are not resolved, it was suggested that might be 
caused by its low aqueous solubility and slow dissolution at the pH range of the stomach and 
low intestine 84. With the aim of increasing the solubility and dissolution rate, a phosphate 
ester of entacapone was presented 85. Phosphate ester of entacapone (34) (Figure 12) 
notably increased the aqueous solubility of the parent drug (over 30 mg/mL at both pH 1.2 
and 7.4 in contrast with that of 33, 0.017 mg/mL at pH 1.2 and 1.75 mg/mL at pH 7.4 and 37 
°C) and showed high stability in both phosphate buffer and human serum, realising 
quantitatively the parent drug in liver homogenate. However, the prodrug strategy failed as 
the prodrug did not yield higher 33 plasma levels in rats 82, which may be result of 33’s low 
intestinal permeability. 
 
HO
HO
NO2
N
N
O
33
O
HO
NO2
N
N
O
34
P
O
O
O
2Na
 
Figure 12. Entacapone (Comtan

) (33) and its phosphate ester prodrug (34). 
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These results suggest the influence of the intestinal permeability of the parent drug in the 
success of a phosphate prodrug strategy. 
3.4. Carbamate Ester Prodrugs of Phenols. 
Carbamate ester prodrugs are usually designed with the aim of either protecting the parent 
phenols against first-pass metabolism following oral administration or as substrates of specific 
enzymes. After hydrolysis, these carbamate esters release the parent drug and carbamic acid 
which is chemically unstable, undergoing to decomposition to amine and CO2. Hansen and 
co-workers 86 suggested the bioconversion of the prodrugs of two dopaminergic 7-
hydroxy3benzazepines via direct carboxylesterase-mediated hydrolysis and cytochrome 
P450-catalyzed hydroxylation to give an N-hydroxymethyl derivative that spontaneously 
decomposes to the N-monomethylcarbamate (Scheme 5).  
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Scheme 5. Pathways for carbamate ester bond cleavage 87. 
 
Carbamate prodrugs may as well undergo conversion to their parent drug via a non-
enzymatic/chemical process. Thomsen and Bundgaard 88 were pioneers in this approach, 
through the preparation and study of cyclization-activated phenyl carbamate prodrugs of 
phenols for protecting them against first-pass metabolism (Scheme 6). 
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Scheme 6. Intramolecular activation of phenyl carbamate prodrugs of phenols 36. 
 
However, the selection of non-enzymatically activated strategies must consider the competing 
enzymatic reactions interfering with the intramolecular cyclization process as well as the 
adverse effects in absorption of the prodrug through biological membranes due to the increase 
in molecular weigh.  
The limited effectivity after oral administration of a class of dopaminergic drugs with 
potential antipsychotic effect, 5-substituted 8-chloro-7-hydroxy-3-methyl-2,3,4,5-tetrahydro-
1H-3-benzazepines, due to glucuronidation of the 7-phenolic group, makes them good 
candidates for prodrug approach. Hansen and co-workers 86 presented various carbamic 
acid esters of this class of drugs. Particularly, carbamate ester prodrug approach was applied 
to 8-chloro-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-
7-ol (35) (Figure 13) which shows a bioavailability of only ~5%. In this study it was found 
that N,N-dimethylcarbamate prodrug (36) (Figure 13) may be a potentially useful prodrug for 
protection against first-pass metabolism. The enzymatic bioconversion of 36 (Scheme 5) 
results in almost quantitative recovery of the parent drug and later studies in dogs 89 
confirmed that the oral administration of prodrug 36 significantly improves the bioavailability 
to approximately 20%. 
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Figure 13. 8-chloro-5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-2,3,4,5-tetrahydro-1H-benzo-
[d]azepin-7-ol (35) and its carbamate ester prodrug (36). 
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As it was shown before, 33 (Figure 12) presents a low bioavailability after oral administration 
(25-35%). Although the reason of its poor bioavailability is unknown, it was suggested that it 
may be the acidic character of 33 (pKa 4.5) which makes it ionise at the pH of small intestine 
84. As is well known, molecules with an ionisable group are better absorbed through the 
intestinal wall when they are present in un-ionised form. On the other hand, low aqueous 
solubility at low pH may obstruct its absorption from the stomach. With the aim to enhance its 
poor bioavailability, Savolainen and co-workers 90 presented various alkyl carbamate esters 
as potential prodrugs of 33. Carbamates of 33 were prepared to increase the lipophilicity of 33 
at neutral pH and to increase the aqueous solubility at an acidic pH. The N-terc-butyl 
carbamate ester (37) (Figure 14) presented higher aqueous solubility at pH 5 as well as higher 
apparent partition coefficient at pH 5 and 7.4 compared to 33. However, the low oral 
bioavailability of 33 was not improved via this strategy. This result agrees with those obtained 
previously 82, where it was concluded that 33 absorption might be controlled by 
permeability. 
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Figure 14. Encacapone carbamate ester prodrug (37). 
 
The presynaptic dopamine autoreceptor agonist (-)-3-(hydroxyphenyl)-N-propylpiperidine(-)-
3-PPP (38) (Figure 15) was developed as an alternative antipsychotic agent in humans 91. 
Following oral administration, 38 was found to have a low bioavailability due to first-pass 
metabolism in the intestinal mucosa and /or in the liver. In order to escape the first-pass 
metabolism in the hepatoportal system and generate high plasma and tissue levels of the 
parent drug, a series of alkyl and arylcarbamate ester derivatives was reported 92. Although 
the alkylcarbamate ester 39 was found to be one of the best prodrug candidates with regard to 
high plasma levels of the parent drug, it was as well found that causes convulsions in rats. 
Prodrugs based on aryl carbamate derivates of 38 were proven to achieve the goal of this 
study. The nature of the substituents in the phenyl ring of the aromatic carbamate derivatives 
seemed to play an important role on the levels of 38 in plasma. As a case in point, more 
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electron donating substituents as in compounds 40 (4-ethoxyphenylcarbamoyl), 41 (4-
isopropylphenylcarbamoyl) or 42 (3,4-dimethoxyphenylcarbamoyl) (Figure 15), strongly 
enhanced the levels of 38 in plasma. 
 
OH
N
H
O
N
H
O
N
H
O
O
N
H
O
N
H
38 40 41
O
N
H
O
N
H
O
O
42
O
N
H
O
N
H
39
Figure 15. 3-(Hydroxyphenyl)-N-propylpiperidine (-)-3-PPP (38) and its carbamate ester 
prodrugs (39, 40, 41, 42). 
 
Terbutaline (43) (Figure 16) is a β2-adrenergic receptor agonist, used as a fast-acting 
bronchodilator (often used as a short-term asthma treatment) and as a tocolytic to delay 
premature labour. Due to its high hydrophilicity, oral absorption varies between 25% and 80% 
of the dose, furthermore, undergoes extensive first-pass sulphate conjugation (69%), causing 
low bioavailability (7% to 26%) 93. Attempts to increase first-pass hydrolytic stability, it 
would be worthwhile to use a carbamate function to protect the phenolic resorcinol hydroxyl 
groups in 43, since the carbamate group is well known moiety which has been used to achieve 
cholinesterase-inhibiting properties of various compounds. Bambuterol (Bambec

) (44) 
(Figure 16) was prepared to examine whether the desired properties could be obtained 
94,95. 44 was found to be a selective cholinesterase inhibitor, resulting in a controlled rate 
of hydrolysis. Furthermore, the dimethylcarbamate moieties resulted to be targets for the 
mixed-function oxidases in the liver, where new carbamate prodrugs of 43 are formed by 
oxidative metabolism. In this respect, 44 may work as a prodrug-prodrug. Finally, 44 and its 
prodrug metabolites seem to facilitate delivery of 43 to the target tissue, the lung. 
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Figure 16. Terbutaline (43) and its carbamate ester prodrug (44). 
Quercetin (45) (Figure 17) is a plant-derived flavonoid with many biological activities 
including inhibition of a number of tyrosine kinases. Due to its extreme water insolubility, 
formulation in dimethylsulfoxide (DMSO) is required. As is well known the use of high doses 
of DMSO causes dose-dependent haemolysis 96,97. To overcome these limitations Qc12 
(46) (Figure 17), a water soluble glycine ester prodrug of 45 was presented 98. After oral 
administration, neither 46 nor 45 was found in serum. However, after i.v. administration, both 
compounds were detected in the serum. The relative availability of 45 obtained following i.v. 
dosing of 46 was found to be in the range of 20-25%. The biggest advantage obtained by the 
utilization of 46 is its high aqueous solubility, eliminating the necessity of DMSO 
formulation. 
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Figure 17. Quercetin (45) and its carbamate ester prodrug (46). 
 
Nitrogen mustard drugs are in common clinical use in cancer chemotherapy as non-specific 
DNA alkylating agents 99. However, their clinical efficacy has been limited due to their 
toxicity to normal tissues. Therefore, selective tumour generation of potent cytotoxic nitrogen 
mustard from a relatively inactive prodrug is desirable. The antibody-directed enzyme 
prodrug therapy (ADEPT) 29 approach was proposed as a solution to the selective liberation 
of the drugs at the surface of the tumour cells. The ADEPT strategy is a two component 
system. In the first step, a tumour selective antibody-enzyme conjugate is administrated. Time 
is allowed to optimize conjugate localization at the tumour. In the second step, a relatively 
non-toxic prodrug is administrated. This prodrug liberates the active drug by enzymatic 
cleavage at the tumour site. In order to optimize the differential cytotoxicity, enzyme kinetics 
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and chemical stability, Springer and co-workers 100 presented a new clinical candidate 
prodrug ZD2767 (48) (Figure 18) for ADEPT. The diiodoethylaminophenol mustard 
glutamate prodrug 48 is hydrolyzed at the carbamate bond by the enzyme carboxypeptidase 
G2, releasing the potent anticancer drug 4-bis(2-iodoethyl)aminophenol mustard (47) (Figure 
18). The novel compound 48 was found to be 100-fold less cytotoxic than the parent drug 47 
when measured in LoVo cells. Furthermore, extremely short life of the candidate (~2min), 
circumvent the potential drawback to leak back into the general circulation after formation at 
the tumour.  
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Figure 18. 4-Bis(2-iodoethyl)aminophenol mustard (47) and its carbamate ester prodrug (48). 
 
Irinotecan hydrochloride trihydrate (Camptosar

) (50) (Figure 18) is a water-soluble 
carbamate prodrug of the lipophilic antineoplastic agent SN-38 (49) (Figure 18) 101. Its 
main use is in colon cancer as an inhibitor of type-I DNA topoisomerase, particularly in 
combination with other chemotherapy agents, this includes the regimen FOLFIRI which 
consists of infusional 5-fluorouracil, leucovorin, and 50 and its clinically administrated as a 
short i.v. infusion. Human liver microsomal carboxylesterases, CES 1A1 and CES2, cleave 
the ester bond of 50 realising the ionisable piperidinopiperidine promoiety and the parent drug 
49 which is 1000-fold more potent inhibitor in vitro of type I DNA topoisomerase than 50 
102.  
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Figure 19. SN-38 (49) and its carbamate ester prodrug (50). 
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Previously in this paper it was shown how due to the poor water solubility of 27 (Fig. 9), a 
phosphate prodrug was developed, 28 (Figure 9) 74,75,76. 28 is rapidly converted to the 
parent drug in vivo and therefore, has been introduced in clinics with the same profile as 27 
itself. A later study 103, presented a prodrug of 27 connected to the -glucuronic moiety by 
a self-immolative spacer (51) (Figure 20), remember that these spacers are used to facilitate 
the enzymatic cleavage of the prodrug. 
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Figure 20. Etoposide carbamate ester prodrug (51). 
 
For this purpose, the therapeutic procedure called prodrug mono therapy (PTM) 104 was 
applied. The prerequisite in this therapy, was to identify an enzyme specifically localize 
around the tumour cells. It was found that necrotic areas in human cancers are the site in 
which lysosomal -glucuronidase is liberated extracellularly in high local concentrations. This 
has led some authors to consider this strategy as available to increase the delivery of 
oncostatic drugs in human tumours 105. The prodrug 51 presented all the requirements in 
vitro for use in a PTM strategy in cancer chemotherapy. It is less toxic than the parent drug 
and quantitatively releases 27 by the action of -glucuronidase (Scheme 7). 
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Scheme 7. Release of etoposide (27) from prodrug 51 103. 
3.5. Sulphamate Ester Prodrugs of Phenols. 
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Natural and synthetic estrogens are used as contraceptives and in tumour therapy. Orally 
administrated estrogens undergo extensive-pass metabolism in the liver resulting in low 
bioavailability and high hepatotoxicity 106. The incorporation of a sulphamate group into 
the steroid nucleus of estradiol (52), estrone (54) and ethinylestradiol (56) (Figure 21) was 
proposed 107 in order to enhance systemic estrogenicity and reduce their hepatotropic 
estrogenic effects at oral administration. 3-sulphamates of estradiol, estrone and 
ethinylestradiol (53, 55, 57) (Figure 21) accumulate in the erythrocytes and pass the liver in 
this compartment without extraction, metabolism and hepatic hormone action, releasing later 
from the erythrocyte compartment to convert into the active compound by the systemic 
hydrolysis of the sulphamate ester (Scheme 8).  
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Figure 21. Estradiol (52) and its sulphamate ester prodrug (53); estrone (54) and its 
sulphamate ester prodrug (55); ethinylestradiol (56) and its sulphamate ester prodrug (57). 
 
Erythrocyte transport is clearly responsible for the significantly improved balance of systemic 
estrogenic activity, which is increased and hepatic estrogenicity, which is much reduced. 
Furthermore, later studies 108 suggested that this type of liver bypass is not associated with 
any measurable adverse effect on erythrocyte oxygen binding, circulatory and blood gas 
functions. In conclusion, steroidal estrogen prodrug approach offers an interesting option to 
overcome limitations of the natural and synthetic steroidal estrogens used in current 
contraceptive regimens.  
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Scheme 8. Pathway for orally administrated estradiol sulphamate prodrug 109.  
 
3.6. Ether Prodrugs of Phenols. 
Ether prodrug approach has been used to enhance lipophilicity, favouring the permeation into 
cellular membranes and the BBB, and/or to improve the pharmacokinetic properties of the 
parent drug. 
Many phenolic group-containing drugs cannot be administrated orally due to their rapid 
metabolism by the enzymes in the intestinal tract and liver 19 and when, ester prodrug 
approach is applied, these derivatives undergo presystemic esterase cleavage in the gut wall to 
liberate the parent drug prematurely. Therefore, a number of types of prodrugs which could 
undergo chemical hydrolysis and not be dependent on esterase activity for their reversion to 
their parent phenols can offer an advantage. One of these types of derivatives is the O-
(imidomethyl) type of prodrug, which undergoes rapid hydrolysis by an SN2 mechanism 
110. In this study, the fastest rate of chemical hydrolysis of the O-(imidomethyl) type 
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derivatives was observed for the O-(saccharinylmethyl) derivative of model phenols (Scheme 
9). 
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Scheme 9. A SN2 Reaction of cleavage for saccharinylmethyl ether prodrugs of phenols 
110. 
 
In this context, Prankerd and co-workers 111 reported an O-(saccharinylmethyl) prodrug 
(58) (Figure 22) of the model compound 52 (Figure 21). As it was said in the last section, 52 
undergoes extensive first-pass metabolism, resulting in an oral bioavailability of only 11% 
112. 58 was found to be totally dependent in chemical and not enzymatic hydrolysis for the 
reversion to its parent phenolic drug. On the other hand, 58 had shown a fast rate of 
hydrolysis in biological media, insuring the release of 52 faster than it is conjugated and 
excreted. Subsequent studies 113 of the oral potency of 58 have suggested that O-
(saccharinyl-methyl) promoiety is a promising candidate for protecting 52 from extensive 
first-pass metabolism and increasing their oral potency. Furthermore, this approach can be 
extended to other phenolic drugs and, another imidomethyl promoieties can be used to form 
chemically labile prodrugs that are insensitive to enzymatic hydrolysis. 
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Figure 22. 17-estradiol ether prodrug (58). 
  
28 
 
PD is a progressive disorder of the central CNS characterized by a reduced concentration of 
the neurotransmitter, dopamine (59) (Figure 23) to the brain. A possible therapy based on the 
used of 59 itself is limited by inability of this substance to cross the BBB. This limitation has 
stimulated the search for prodrug strategies that rely on dopamine-derivatives able to 
penetrate the BBB, by making use of specific transport systems. Ferdández-Mayoralas and 
co-workers 114 initiated studies on a new approach to deliver 59 by linking the 
neurotransmitter to a sugar molecule, resulting in a glycoconjugate that may cross the BBB 
using the glucose carrier GLUT-1. As is well known, glucose is the brain’s source of energy 
and other hexoses are transported across the BBB by GLUT-1 115. Once transported into 
the CNS the prodrug should be enzymatically cleaved to release the active compound 
(Scheme 10). 
 
 
Dopamine
GLUT-1
Glucose
Bioactivation
(glycosidase)
BRAIN
Prodrug
 
Scheme 10. Schematic representation of the new strategy to deliver dopamine into the CNS 
114. 
 
Two prodrugs of dopamine (60, 61) (Figure 23) where the sugar was attached to the phenolic 
groups of 59 were presented. Glycosides 60 and 61 fulfilled the prodrug criteria since they 
showed high stability in plasma and a sustained release of dopamine in brain extract through 
an activation mechanism catalysed by glycosidase. Unfortunately they did not exhibit in vivo 
antiparkinsonian properties. Later studies 116 demonstrated that the factor responsible for 
the absence of in vivo activity is the lack of affinity of the glycosyl derivatives 60 and 61 for 
the glucose carrier GLUT-1.  
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Figure 23. Dopamine (59) and its ether prodrugs (60, 61). 
 
Approaches to increasing topical delivery by transiently masking a phenolic functionality 
have been recently investigated. The soft alkyl analogues of alkyoxycarbonyl (AOC) prodrugs 
obtained by inserting an –NR´CH2– between the carbonyl carbon and the phenol oxygen to 
form N-alkyloxycarbonylaminomethyl (NANAOCAM) using the model drug 
acetaminophenol (APAP) (62) (Figure 24) was presented 117. It was found that the 
insertion of –NR´CH2– into the AOC promoiety increased the biphasic solubility and the flux 
of 62 compared with AOC-APAP 118. The most effective derivative (N-methyl-N-
methyloxycarbonylamino-methyl prodrug) (63) (Figure 24) at enhancing the delivery of total 
62 species through mousses skin from isopropyl mirystate (IPM) was found to be the most 
water soluble member of this more lipid soluble series. However NANAOCAM derivatives of 
62 were poorly converted to 62 in diffusion cell experiments. The poor bioconversion of these 
derivatives limits their application in topical delivery. Recently, Sloan and co-workers 119 
have presented a series of alkylcarbonyloxymethyl (ACOM) derivatives of 62, where a –
OCH2– spacer separates the carbonyl moiety from the parent drug. In this study, the flux of 
the most permeable derivative (ethylcarbonyloxymethyl prodrug) (64) (Figure 24)” was 3.6 
times greater than that of 62 and just 9% of the intact prodrug was found in the receptor 
phase. High stability in IPM solution of theses derivatives showed that the absence of intact 
prodrug in the receptor phase was due to extensive enzymatic hydrolysis in the skin and was 
not the result of substantial chemical hydrolysis in the receptor or donor phases. The results 
presented in this study 119 demonstrate for the first time that ACOM derivatives are capable 
of improving the topical delivery of a phenol. 
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Figure 24. Acetaminophen (62) and its ether prodrugs (63, 64). 
 
3.7. Conclusion. 
Prodrugs continue to be an exciting area of research due to the significant delivery challenges 
that present more and more drug candidates. The examples provided in this review 
demonstrate the diverse array of prodrugs options in improving poor delivery characteristics 
and solubility limitations of phenolic drugs. 
While this chapter does not represent an exhaustive review of all the prodrug approaches for 
improved the characteristics of phenolic group-containing drugs, it does provide a suitably 
general view of the different prodrug strategies to give the readers a comprehension for the 
choice and limitations of this approach and the tasks scientists are dealing with in improving 
phenolic group-containing therapeutics with the use of prodrugs. 
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4. Salicylanilide Modification. 
4.1. Introduction. 
SAL are an important class of aromatic compounds with a wide range of pharmacological 
activities, such as antibacterial120,121,122,123, antifungal 124 and anti-inflammatory 
125, among others. Furthermore; several studies reported their potent antimycobacterial 
123,126 effect. Their activity results from multiple mechanisms. SAL were identified as 
inhibitors of the two-component regulatory systems 127 of bacteria 128,129 by a 
mechanism related to the effects on uncoupling oxidative phosphorylation. Later on, they 
were found to be inhibitors of the protein kinase epidermal growth factor receptor 130,131, 
by the competition with ATP for binding at the catalytic domain of tyrosine kinase and to stop 
the tumour growth. The pseudo six-member ring facilitated by a strong intramolecular 
phenolic hydroxyl-carbonyl hydrogen bond seems to be significant for their activity 132. In 
recent studies, they were also found to be selective inhibitors of interleukin-12p40 production 
that play an specific role in the initiation, expansion and control of the cellular response to TB 
as well 133,134. 
In general, an electron-withdrawing group on the salicyloyl ring and hydrophobic groups on 
the anilide moiety, as well as the 2-hydroxy group, are essential for the optimal antimicrobial 
effect. The salicylanilides substituted with halogens in both parts meet the requirements and 
form the most active derivatives with anti-TB activity against M. tbc. and some atypical 
strains of mycobacteria120. 
Although the presence of phenolic hydroxyls seems to be necessary for the activity of these 
compounds also limits their bioavailability and thus their effectivity. 
Our strategy in the design of new potential antimycobacterial active agents has been mainly 
orientated towards the synthesis of prodrug forms of the most anti-TB active SAL in order to 
improve their physico-chemical and pharmacokinetic properties, enlarge their activity profile 
and protect the phenolic hydroxyl against first-pass metabolism. 
4.2. Amino acid esterification (Paper II, Paper III). 
Esterification of the hydroxyl(s) group has been one of the preferred prodrug strategies in 
order to temporally mask polar groups resulting in an increased lipophilic molecule, which 
would promote membrane permeability.  
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For the development of a general synthetic method for SAL esterification, protected lipophilic 
simple amino acids (AA) were chosen for being natural molecules which will increase 
lipophilicity of the parent corresponding SAL. 
The series of the above-mentioned salicylanilide derivatives was synthesized in two steps. 
The starting SAL 1 were selected according to previous results showing high in vitro activity 
against M. tbc. 135. They were routinely prepared by the reaction of 4 or 5-chlorosalicylic 
acid with the appropriate aniline in chlorobenzene with PCl3. By using microwave irradiation, 
the reaction time was shortened from several hours to minutes. In a second step, N-
benzyloxycarbonyl AA (N-Cbz-AA) 2 were esterified with the corresponding SAL 1 by using 
N,N’-dicyclohexylcarbodiimide (DCC) activation as an optimal method 136. Lipophilic N-
Cbz-AA such as glycine (Gly), R/S-alanine (Ala), R/S-valine (Val) and R/S-phenylalanine 
(Phe) were used for esterification. As expected, in most of the cases the reaction gave the 
desired esters 3 in high yields. The general synthetic pathway is shown in Scheme 11. 
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Scheme 11. Synthesis of investigated salicylanilide derivatives. Reagents and conditions: (a) 
DCC, DMF, -10°C. 
 
All the prepared N-Cbz-AA esters 3 were tested in vitro for their antimycobacterial activity in 
the National Reference Laboratory for M. kansasii, against M. tbc. (331/88) and against some 
non-TB strains such as M. avium (330/88) and M. kansasii (235/80 and 6509/96), where the 
first line drug INH shows no activity. All the 30 SAL esters showed high antimycobacterial 
activity against all tested mycobaterial strains with minimum inhibition concentration (MIC) 
values in the range of 1 – 32 mol/L. The anti-TB screening results of the most active 
compounds are summarized in Table 1. 
Hydrophobicities (log P/Clog P values) of the studied compounds 3 were calculated using 
two commercially available programs (CHEMDRAW Ultra 10.0 and ACD/logP) and measured by 
means of RP-HPLC determination of capacity factors k with subsequent calculation of log k 
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137. In general, the levels of anti-TB activity of the synthesized compounds 3 suggest that 
lipophilicity is a secondary parameter for anti-TB activity and there is no correlation between 
log k and the anti-TB activity of these compounds (See Table 1).  
 
Table 1. Antimycobacterial activity and lipophilicity of the most active SAL Cbz-amino acid 
esters 3. 
 R1 R2 R3 MIC (M) Lipophilicity factor 
    
M. tbc 
331/88 
M. avium 
330/88 
M. kansasii 235/80 
M. kansasii 
6509/96 log k 
log P 
ACD/log P 
log P/Clog P 
ChemOffice 
    14d 21d 14d 21d 7d 14d 21d 7d 14d 21d 
3a 4-Cl 4-Br (S)-CH-(CH3)2 4 4 8 16 4 8 8 8 8 8 0.980 6.410.54 6.36/6.5332 
3b 4-Cl 4-Br (R)-CH-(CH3)2 2 4 16 16 4 8 8 8 8 8 0.980 6.410.54 6.36/6.5332 
3c 4-Cl 4-Br (R)-CH2-Ph 2 4 8 16 2 4 4 8 8 8 1.126 7.460.55 7.15/7.0232 
3d 5-Cl 4-Cl (R)-CH-(CH3)2 4 4 8 16 4 8 8 4 8 8 0.881 5.610.48 6.09/6.3832 
3e 5-Cl 4-Cl (S)-CH2-Ph 4 4 8 8 4 8 8 4 8 8 1.030 7.560.49 6.88/6.8732 
3f 5-Cl 4-Cl (R)-CH2-Ph 4 4 8 8 4 8 8 4 8 8 1.030 7.560.49 6.88/6.8732 
INH    0.5 0.5 250 250 250 250 250 4 8 8    
 
The most active compounds (3a-3f) were chosen for further investigation. Cytotoxicity 
assessment made on human intestinal cell line HCT-8 (ECACC, UK) showed medium 
cytotoxicity for all the measured compounds in comparison to the standard INH. Furthermore, 
the selectivity index (SI), defined as the ratio of the concentration inhibiting 50% of the cell 
growth (EC50) to MIC, was higher than 10 (see Table 2), what makes them good candidates 
for additional screening 138.   
The hydrolytic stability of the most active compounds (3a-3f) was as well investigated. To 
simulate blood or serum and afflicted tissue, the stability in two types of phosphate buffer at 
pH 7.4 (7 x 10
-2
 M, 37°C) and pH 5.5 (7 x 10-2 M, 37°C) was measured using UV/Vis 
spectroscopy 139. From experimental data measured at 224 nm, the half-times (t1/2) and rate 
constants (kobs) were calculated and the results are summarized in Table 2. The experimental 
results for both types of hydrolysis are comparable, being acidic hydrolysis slightly faster.  
 
Table 2. Rate constants and half-times of the most active compounds in phosphate buffer 
solution pH 7.4 and 5.5. 
 
Rate constant 
kobs (s
-1) pH 7.4 
t1/2 (s) for pH 7.4 
Rate constant 
kobs (s
-1) pH 5.5 
t1/2 (s) for pH 5.5 EC50 (M) SI for M. tbc. 
3a 
3b 
3c 
3d 
3e 
3f 
7.79 x 10
-4
 
7.70 x 10
-4
 
3.37 x 10
-4
 
5.65 x 10
-4
 
4.56 x 10
-4
 
5.24 x 10
-4 
889.94 
897.47 
2057.70 
1226.10 
1520.80 
1323.30 
8.06 x 10
-4
 
7.81 x 10
-4
 
3.56 x 10
-4
 
5.69 x 10
-4
 
5.29 x 10
-4
 
4.35 x 10
-4
 
860.10 
887.25 
1948.50 
1218.10 
1311.50 
1074.00 
121.8 
121.3 
35.5 
106.7 
82.9 
104.2 
16.74 
33.35 
10.61 
13.75 
20.73 
26.05 
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4.2.1. Unexpected formation of novel seven-membered ring benzoxazepines (Paper IV). 
In the course of our research, we found that N-Cbz-Gly 2 (R
3
=H) or N-Cbz-(S)-Ala (R
3
=CH3), 
when esterified with salicylanilides 2 (R
1
=5-Cl, R
2
=4-Cl, 4-Br, 4-CF3, 3-Cl) underwent to 
seven-membered rings of benzoxazepine-2,5-diones 5. The structure of the final product was 
unequivocally determined by mass spectroscopy and 2D NMR experiment (gHMBC). We 
proposed a possible mechanism for this rearrangement where the attack of the amide carbonyl 
by the carbamic NH group would give rise to a seven-membered cyclic intermediate 4, which 
would further react with the substituted aniline released as a leaving group in the previous 
step, to result in the final product 5 (See Scheme 12).  
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Scheme 12. Possible mode of cyclization. 
 
Biological testing was provided for the series of 9 unexpected bezoxazepine-2,5-diones 5 
against M. tbc. (331/88), M. avium (330/88) and M. kansasii (235/80 and 6509/96). Unluckily, 
these cycles doesn’t present anti-TB activity. 
4.3. Alkyl carbamate esterification (Paper V). 
In the recent past, a number of organic carbamates 140 have been found as potential 
antibacterial and antiviral agents. The carbamate residue present in these new molecules either 
contributes as a core component 141 or incorporated into a known molecule, contributes to 
the improvement of its pharmacodynamic and pharmacokinetic properties 142,143. In 
particular, carbamate was successfully used to protect phenolic drugs 144,145. 
Thus, we hypothesised that masking the phenolic hydroxyl in SAL by carbamate formation 
may protect the molecule against extensive first-pass metabolism following oral 
administration, broaden its activity profile and improve its physicochemical and 
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pharmacokinetic properties. In this context, the aim of this article was to describe the 
synthesis, antimycobacterial activity and cytotoxicity of a series of SAL carbamates as well as 
to evaluate their stability against chemical hydrolysis at various pH values.  
The preparation of the carbamates is outlined in Scheme 13. The synthesis of the starting 
SAL 1 has been described in the previous chapter.  
For the synthesis of the corresponding carbamates 7, a suspension of SAL 1 in acetonitrile 
(ACN) was treated with one equivalent of triethylamine (TEA), adding then the 
corresponding isocyanate 6. This reaction was performed at room temperature due to thermal 
instability of the products. The prepared carbamates 7 belong into three series: those having 
chlorine at position 3, at position 4, and at positions 3 and 4, respectively, of the anilide ring. 
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Scheme 13. Synthesis of 4-chloro-2-(R
1
-chlorophenylcarbamoyl)phenyl alkylcarbamates.  
Reagents and conditions: (a) PCl3, chlorobenzene, microwave irradiation (530 W); (b) TEA, 
ACN, rt. 
 
The prepared carbamates 7 were tested in vitro for their antimycobacterial activity in against 
M. tbc. (331/88) and against some non-TB strains such as M. avium (330/88) and M. kansasii 
(235/80 and 6509/96). The anti-TB screening results of the most active compounds of this 
series are summarized in Table 3. 
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Table 3. Antimycobacterial activity and calculated lipophilicity of the most active SAL 
alkylcarbamates 7. 
 MIC [mol/L 
log P/ClogP 
  R
1
 R
2 
M. tbc 
331/88 
M. avium 
330/88 
M. kansasii 
235/80 
M. kansasii 
6509/96 
14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 
7a 
7b 
7c 
7d 
7e 
7f 
7g 
7h 
INH 
3-Cl 
3,4-diCl 
3,4-diCl 
3,4-diCl 
3,4-diCl 
3,4-diCl 
3,4-diCl 
4-Cl 
- 
hexyl 
ethyl 
butyl 
pentyl 
hexyl 
heptyl 
octyl 
pentyl 
- 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
1 
1 
0.5 
0.5 
1 
1 
0.5 
0.5 
8 
16 
8 
8 
4 
4 
4 
8 
250 
8 
32 
16 
16 
8 
8 
8 
8 
250 
4 
2 
2 
2 
2 
2 
2 
2 
250 
4 
4 
2 
2 
2 
2 
4 
4 
250 
4 
2 
2 
2 
1 
2 
2 
4 
4 
4 
4 
4 
4 
2 
4 
4 
4 
4 
5.53/6.31 
4.35/4.82 
5.25/5.88 
5.67/6.41 
6.08/6.93 
6.50/6.46 
6.92/7.99 
5.11/5.78 
- 
 
In this study, the most active derivatives resulted to be those with logP values of 
approximately 6. Although the higher lipophilicity may be the reason for the increase in the 
activities of the carbamates 7 against M. tbc., kansasii and avium compared to the starting 
SAL 135, it cannot explain their higher potency compared to the corresponding N-protected 
AA ester derivatives 3, whose lipophilicities are comparable 146. For example, compound 
7e was 16 times more potent than the parent SAL and 4 times more active than the most 
active corresponding N-protected AA ester derivative against M. tbc. (331/88). 
The most active derivatives of this series were tested as well against five clinically isolated 
MDR-TB strains, including M. tbc. 7357/98, resistant to INH, RMP, EMB, STM, ofloxacin 
(OFX) and ansamycin, M. tbc. 9449/06, resistant to IHN, STM, RMP and ansamycin, M. tbc. 
2092/05, resistant to INH, RMP, EMB, STM, OFX and ansamycin, M. tbc. Praha 1, resistant 
to INH, RMP, EMB, STM, clofazimine (CFZ) and ansamycin, and M. tbc. Praha 128 resistant 
to IHN, RMP, EMB, STM, gentamicin (GTM), CFZ, ansamycin and amikacin (AK). All the 
studied compounds exhibited high activity against the MDR-TB strains, with MIC values 
between 0.5-2 mol/L (Table 4). These activities are comparable with that presented by 
compounds undergoing PhaseII clinical trials such a nitroimidazopyran PA-824 147,148, 
with MIC values between 0.1-0.7 mol/L against mono and MDR-TB strains or the diamine 
analogue of EMB, SQ109 149,150, with MIC values between 0.5-1.8 mol/L against strains 
resistant to EMB, IHN and RMP. 
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Table 4. Activity of selected carbamates against MDR-TB strains. 
 
MIC [mol/L 
EC50 
[mol 
/L 
SI SI 
M. tbc 
331/88 
M. tbc 
7357/98a 
M. tbc 
9449/06b 
M. tbc 
2092/05c 
M. tbc 
Praha 1d 
M. tbc 
Praha 128e 
For 
MTB 
For 
MDR-
TB 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 14 d 21 d 
7a 
7b 
7c 
7d 
7e 
7f 
7g 
7h 
INH 
0.5 
1 
0.5 
0.5 
0.5 
0.5 
1 
0.5 
0.5 
1 
1 
1 
0.5 
0.5 
1 
1 
0.5 
0.5 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
1 
16 
1 
1 
1 
0.5 
1 
0.5 
1 
2 
16 
1 
0.5 
1 
0.5 
0.5 
0.5 
1 
1 
16 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
16 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
16 
2 
0.5 
1 
0.5 
0.5 
1 
1 
1 
16 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
1 
16 
2 
1 
1 
1 
1 
1 
2 
2 
16 
1 
0.5 
0.5 
0.5 
0.5 
0.5 
0.5 
1 
16 
2 
0.5 
1 
0.5 
0.5 
1 
1 
1 
16 
14.9 
31.0 
38.0 
40.0 
27.9 
43.4 
48.5 
17.4 
>100 
14.9 
31.0 
38.0 
80.0 
55.8 
43.4 
48.5 
34.8 
>200 
7.4-14.9 
31-62 
38-76 
40-80 
28-56 
43.4-86.8 
24-97 
8.7-17.4 
>6.25 
aResistant to INH, RMP, EMB, STM, OFX and ansamycin 
bResistant to INH, STM, RMP and ansamycin 
cResistant to INH, RMP, EMB, STM, OFX and ansamycin 
dResistant to INH, RMP, EMB, STM, CFZ and ansamycin 
eResistant to INH, RMP, EMB, STM, GTM, CFZ, ansamycin and AK 
 
 
The in vitro mammalian cell toxicity of the most active compounds 7 was assessed on human 
intestinal cell line HCT-8 (ECACC, UK) using the XTT assay 151. The cytotoxicity results 
presented in Table 4 are expressed as the EC50. The studied compounds show moderate 
cytotoxicity in comparison to the standard INH with the EC50 values in the range of 14.9 – 
48.5 mol/L. Nevertheless, all the studied compounds displayed the SI value higher than 10 
for both TB and MDR-TB strains (Table 4), what means that they should be seriously 
considered for further screening 138. 
The chemical hydrolysis of compound 7e was studied in aqueous buffer solutions at pH from 
3 to 8 at 37 °C. The decomposition of 7e and the release of the parent SAL were monitored by 
HPLC for 48 h. The carbamate bond was stable at acidic pH values but decomposed in 
alkaline environment following a pseudo-first order kinetics (Table 5). 
At physiological pH of 7.4, the carbamate 7e showed a t1/2 of almost 2 days. Although these 
data describe chemical hydrolysis only, we hypothesize that these compounds may also be 
stable in plasma for sufficient time to reach its site of action, i. e. the mycobacteria. This 
assumption is supported by the relative stability of the carbamate bond towards esterases 
152. Moreover, in a previous study, a carbamate of a similar structure displayed a t1/2 of 
15.9 and 2.7 h in a buffer and plasma, respectively 90. In addition, due to the stability in 
acidic environment, these compounds may be good candidates for oral administration. 
Furthermore, protection of the phenolic hydroxyl may render the compound less susceptible 
towards first-pass metabolism. However, the stability of the synthesized SAL carbamates in 
biological environments and their bioavailability warrants further investigation. 
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Table 5. Half-lives (t1/2 ) of the carbamate 7e at various pH values. 
pH t1/2 (h) 
3 
4 
5 
6 
7 
7.4 
8 
nd 
nd 
nd 
185  68 
64  8 
43  6 
5  2 
Mean ± SEM, n = 3 
nd = no significant decomposition observed (p < 0.05) 
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5. Rearrangement of salicylanilide derivatives 
5.1. Unexpected formation of 2-Hydroxy-N-(1-(oxo-(phenylamino)-alkan-2-
yl)benzamides. 
As a part of our ongoing search for new antituberculosis active molecules of SAL esters, we 
proceeded to the deprotection of the synthesized N-Cbz-AA esters 3. The N-deprotection of 
the amino group failed under generous conditions of hydrogenolysis (H2/Pd) – the ester 
linkage was found unstable even if different reaction conditions and solvents were used 
(temperature modification, toluene, ethylacetate, methanol solvents). Amino group liberation 
was finally realized using 33 % solution of hydrogen bromide (HBr) in glacial acetic acid 
(AcOH) in absence of solvent. Diethyl ether (DEE) addition precipitated the appropriate HBr 
salts of SAL-AA esters as white hygroscopic solids 8 in almost quantitative yields. 
Subsequent amino group liberation by TEA under anhydrous conditions yielded the 
unexpected product 9 in which there was no signal either of ester or of free amino group, only 
the presence of a phenolic hydroxyl was clearly detected. The structure of 9 was 
unequivocally corroborated by HMBC 2D NMR experiments. Unexpected rearrangement 
products after amino group liberation were identified as substituted hydroxy-N-
(phenylamino)-oxo-alkyl)benzamides, “diamides” 9 (Scheme 14). 
 
N
H
O
O
O
H
N O
OR3
R1
R2
N
H
O
O
O
NH3
+Br-
R3
R1
R2
b
OH
O
N
H
O
HN
R1
R2
R3
a
3 8 9
R1 = 4-Cl; 5-Cl
R2 = 4-Cl; 4-Br; 3-Cl; 3,4-diCl
R3 = H; Me; i-Pro; -CH2-Ph
Scheme 14. Synthesis of substituted hydroxy-N-(phenylamino)-oxo-alkyl)benzamides 9.  
Reagents and conditions: (a) AcOH/HBr, rt; (b) TEA, rt. 
 
These series of hydroxy-N-(phenylamino)-oxo-alkyl)benzamides 9 were tested in vitro for 
their antimycobacterial activity in the National Reference Laboratory for M. kansasii, against 
M. tbc. (331/88) and against some non-TB strains such as M. avium (330/88) and M. kansasii 
(235/80 and 6509/96). The results are presented in Table 6. 
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Table 6. Antimycobacterial evaluation of Hydroxy-N-(phenylamino)-oxo-alkyl benzamides 9. 
 R1 R2 R3 
MIC (M) 
M. tbc 
331/88 
M. avium 
330/88 
M. kansasii 235/80 
M. kansasii 
6509/96 
14d 21d 14d 21d 7d 14d 21d 7d 14d 21d 
9a 4-Cl 4-Br (S)-CH-(CH3)2 62.5 62.5 62.5 62.5 62.5 62.5 125 62.5 62.5 62.5 
9b 4-Cl 4-Br (R)-CH-(CH3)2 62.5 62.5 125 125 62.5 62.5 125 32 62.5 62.5 
9c 4-Cl 4-Br (R)-CH2-Ph 32 32 250 250 32 62.5 500 62.5 125 250 
9d 5-Cl 4-Cl (R)-CH-(CH3)2 62.5 62.5 62.5 62.5 16 32 62.5 32 62.5 62.5 
9e 5-Cl 4-Cl (S)-CH2-Ph 32 32 32 62.5 32 32 32 32 32 32 
9f 5-Cl 4-Cl (R)-CH2-Ph 32 32 62.5 62.5 32 32 62.5 32 62.5 62.5 
9g 5-Cl 4-Cl (R)-CH3 8 16 62.5 125 32 125 250 62.5 125 250 
9h 5-Cl 4-Cl (S)-CH-(CH3)2 32 32 62.5 62.5 32 62.5 62.5 32 62.5 62.5 
9i 5-Cl 4-Cl (R)-CH-(CH3)2 32 32 62.5 62.5 32 62.5 62.5 32 62.5 62.5 
9j 5-Cl 4-Cl (S)-CH2-Ph 16 16 32 32 32 32 62.5 16 32 62.5 
9k 5-Cl 4-Cl (R)-CH2-Ph 16 16 32 32 16 32 32 32 32 62.5 
9l 5-Cl 4-Br (S)-CH2-Ph 32 32 250 250 32 62.5 500 62.5 125 250 
9m 5-Cl 3,4-diCl H 125 500 62.5 500 62.5 125 500 62.5 250 500 
9n 5-Cl 3,4-diCl (S)-CH3 32 32 62.5 32 32 62.5 >500 62.5 62.5 32 
9o 5-Cl 3,4-diCl (S)-CH-(CH3)2 32 32 62.5 125 16 32 62.5 16 32 62.5 
9p 5-Cl 3,4-diCl (R)-CH-(CH3)2 16 32 62.5 125 16 32 62.5 16 32 32 
9q 5-Cl 3,4-diCl (S)-CH2-Ph 125 >1000 125 >1000 125 250 >1000 62.5 250 500 
9r 5-Cl 3,4-diCl (R)-CH2-Ph 125 >1000 125 >1000 32 62.5 500 32 62.5 500 
9s 4-Cl 4-Cl (S)-CH3 62.5 62.5 125 125 62.5 125 125 125 62.5 62.5 
9t 4-Cl 4-Cl (R)-CH3 32 62.5 125 125 62.5 125 125 62.5 62.5 62.5 
9u 4-Cl 4-Cl (S)-CH-(CH3)2 62.5 62.5 125 125 32 62.5 62.5 32 62.5 62.5 
9v 5-Cl 3-Cl H 125 125 62.5 62.5 125 250 250 62.5 250 250 
9w 5-Cl 3-Cl (S)-CH3 250 500 500 500 125 500 500 250 500 500 
9x 5-Cl 3-Cl (R)-CH3 62.5 125 125 250 62.5 62.5 62.5 32 62.5 62.5 
9y 5-Cl 3-Cl (S)-CH-(CH3)2 32 62.5 125 125 62.5 62.5 125 32 62.5 62.5 
9z 5-Cl 3-Cl (R)-CH-(CH3)2 32 62.5 62.5 125 62.5 62.5 125 32 62.5 62.5 
9aa 5-Cl 3-Cl (S)-CH2-Ph 62.5 125 125 250 32 62.5 125 16 32 32 
9bb 5-Cl 3-Cl (R)-CH2-Ph 62.5 62.5 32 32 62.5 62.5 62.5 32 62.5 62.5 
INH - - - 0.5 0.5 250 250 250 250 250 4 8 8 
 
Although synthesized compounds 9 show some activity, we observed an important decrease 
of the activity compared with the starting SAL 135 or the corresponding N-Cbz-AA ester 
derivatives 3 146. Take as example the compound 9c, which presented 2 times less potency 
than the parent SAL and 8 times less potency than the corresponding N-Cbz-AA ester. 
However, we have developed an alternative synthetic route for this kind of “diamides”. In the 
recent past, for example, Shibasaki and co-workers 153 have presented the diamide (S)-2-
hydroxy-N-(1-(2-hydroxyphenylamino)-3-methyl-1-oxobutan-2-yl)benzamide as a promising 
ligand for the amination of succinimide in the catalytic asymmetric synthesis of AS-3201. 
AS-3201 was identified as a structurally novel aldose-reductase inhibitor used in the treatment 
of diabetic disorders. 
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5.1.1. Hydrobromide salts of α-amino acid esters and salicylanilides 8. 
General procedure  
A solution of hydrogen bromide in acetic acid (33%) (6 mL) was slowly added to N-
benzyloxycarbonyl-protected esters 3 (2 mmol) with stirring. The suspension was stirred at 
room temperature for 30 min. during this time, the suspension turned into a clear brown 
solution, and evolution of carbon dioxide was observed. When the gas evolution ceased, dry 
diethyl ether DEE was added. The precipitate was collected by filtration, washed with DEE (3 
x 15 ml) and dried. The isolated crystals were suspended in dry chloroform at room 
temperature, filtered and dried in vacuo at room temperature. The yield of hydrobromide salt 
8 was about 90 %. 
Data of prepared hydrobromide salts 8 
(S)-1-(2-(4-Bromophenylcarbamoyl)-4-chlorophenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8a. 
White solid; yield 91%; mp 198-203 °C. IR (KBr pellet): 3420, 2969, 1757 (CO ester), 1663, 
1592, 1515, 1490, 1394, 1198, 1105, 1072, 1011, 918, 818, 505 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 10.72 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.83 (1H, d, J=2.7 Hz, H3), 7.68-7.64 
(2H, m, AA´, BB´, H2´, H6´), 7.58 (1H, dd, J=8.5 Hz, J=2.7 Hz, H5), 7.55-7.52 (3H, m, H6, 
H3´, H5´), 4.20 (1H, m CH), 2.31-2.25 (1H, m, CH), 0.98 (3H, d, J=6.5 Hz, CH3), 0.96 (3H, 
d, J=6.5 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 162.7, 155.1, 145.7, 138.3, 132.1, 
131.8, 131.5, 131.0, 129.3, 129.0, 125.1, 121.8, 115.9, 57.6, 29.3, 18.0, 17.8. 
(R)-1-(2-(4-Bromophenylcarbamoyl)-4-chlorophenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8b. 
White solid; yield 93%; mp 180-185 °C. IR (KBr pellet): 3421, 2969, 1756 (CO ester), 1667, 
1592, 1518, 1490, 1394, 1313, 1291, 1198, 1105, 1072, 1011, 818, 655, 505 cm
-1
. 
1
H NMR 
(300 MHz, DMSO) 10.71 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.83 (1H, d, J=2.7 Hz, 
H3), 7.74-7.65 (2H, m, AA´, BB´, H2´, H6´), 7.58 (1H, dd, J=8.8 Hz, J=2.7 Hz, H5), 7.40-
7.30 (3H, m, H6, H3´, H5´), 4.20 (1H, m CH), 2.31-2.25 (1H, m, CH), 0.98 (3H, d, J=6.5 Hz, 
CH3), 0.96 (3H, d, J=6.5 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 162.7, 155.1, 145.7, 
138.3, 132.2, 131.8, 131.5, 131.0, 129.3, 129.0, 124.1, 121.8, 115.9, 56.6, 29.3, 18.0, 17.9. 
(R)-1-(2-(4-Bromophenylcarbamoyl)-4-chlorophenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8c. 
White solid; yield 93%; mp 200-202 °C. IR (KBr pellet): 2857, 1762 (CO ester), 1663, 1591, 
1517, 1490, 1395, 1312, 1205, 1105, 1072, 1010, 820, 703 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.72 (1H, bs, NH), 8.64 (3H, bs, NH2.HBr) 7.87 (1H, d, J=2.4 Hz, H3), 7.75-7.69 (3H, m, 
H4, H2´, H6´), 7.33-7.22 (8H, m, H6, H3´, H5´, H2´´, H3´´, H4´´, H5´´, H6´´), 4.54 (1H, m, 
CH), 3.29 (1H, dd, J=14.4 Hz, J=6.9 Hz, CH2), 3.14 (1H, dd, J=14.4 Hz, J=6.6 Hz, CH2). 
13
C 
NMR (75 MHz, DMSO)  167.3, 163.2, 155.1, 142.2, 138.3, 133.6, 132.5, 131.8, 129.7, 
129.5, 128.6, 126.9, 123.3, 122.5, 122.1, 118.0, 53.6, 28.3. 
(R)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8d. 
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White solid; yield 97%; mp 192-198 °C. IR (KBr pellet): 3412, 3294, 2969, 1759 (CO ester), 
1662, 1605, 1595, 1515, 1493, 1399, 1312, 1196, 1158, 1095, 1014, 910, 887, 827, 581, 508 
cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.70 (1H, bs, NH), 8.53 (3H, bs, NH2.HBr), 7.77 (1H, 
d, J=8.1 Hz, H3), 7.74-7.71 (2H, m, AA´, BB´, H2´, H6´), 7.60-7.54 (2H, m, AA´, BB´, H3´, 
H5´), 7.41-7.36 (2H, m, H4, H6), 4.16 (1H, m, CH), 2.34-2.23 (1H, m, CH), 0.98 (3H, d, 
J=5.1 Hz, CH3), 0.96 (3H, d, J=5.1 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.6, 163.2, 
157.1, 147.7, 138.0, 135.5, 130.8, 129.6, 129.2, 128.9, 128.8, 127.1, 123.4, 121.4, 57.7, 21.7, 
18.0, 17.9. 
(S)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8e. 
White solid; yield 96%; mp 184-186 °C. IR (KBr pellet): 3411, 2857, 1771 (CO ester), 1652, 
1601, 1526, 1493, 1399, 1315, 1199, 1094, 1013, 906, 827, 752, 701, 508 cm
-1
. 
1
H NMR (300 
MHz, DMSO) 10.68 (1H, bs, NH), 8.61 (3H, bs, NH2.HBr), 7.82 (1H, d, J=8.4 Hz, H3), 
7.76-7.74 (2H, m, AA´, BB´, H2´, H6´), 7.37 (1H, dd, J=8.4 Hz, J=2.1 Hz, H4), 7.43-7.39 
(2H, m, AA´, BB´, H3´, H5´), 7.38 (1H, d, J=2.1 Hz, H6), 7.33-7.24 (5H, m, H2´´, H3´´, 
H4´´, H5´´, H6´´), 4.53 (1H, m, CH), 3.30 (1H, dd, J=14.1 Hz, J=6.6 Hz, CH2), 3.14 (1H, dd, 
J=14.1 Hz, J=6.6 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.3, 163.1, 148.0, 138.0, 135.8, 
134.7, 131.2, 129.7, 129.6, 129.3, 128.9, 128.8, 127.6, 126.9, 122.5, 119.6, 53.6, 28.3. 
(R)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8f. 
White solid; yield 91%; mp 196-198 °C. IR (KBr pellet): 3420, 1771 (CO ester), 1654, 1594, 
1523, 1493, 1400, 1315, 1199, 1094, 828, 701, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.65 (1H, bs, NH), 8.60 (3H, bs, NH2.HBr), 7.81 (1H, d, J=8.7 Hz, H3), 7.75-7.73 (2H, m, 
AA´, BB´, H2´, H6´), 7.37 (1H, dd, J=8.7 Hz, J=2.2 Hz, H4), 7.44-7.39 (2H, m, AA´, BB´, 
H3´, H5´), 7.38 (1H, d, J=2.2 Hz, H6), 7.35-7.25 (5H, m, H2´´, H3´´, H4´´, H5´´, H6´´), 4.52 
(1H, m, CH), 3.30 (1H, dd, J=14.1 Hz, J=6.6 Hz, CH2), 3.14 (1H, dd, J=14.1 Hz, J=6.6 Hz, 
CH2). 
13
C NMR (75 MHz, DMSO)  167.2, 163.1, 148.0, 138.0, 135.8, 134.9, 131.2, 129.7, 
129.6, 128.9, 128.8, 127.8, 127.5, 127.1, 123.4, 121.7, 53.6, 30.6. 
(R)-1-(4-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 8g. 
White solid; yield 89%; mp 191-194 °C. IR (KBr pellet): 3421, 2939, 1772 (CO ester), 1659, 
1595, 1519, 1493, 1399, 1314, 1202, 1105, 1014, 820, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.68 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.86 (1H, d, J=2.7 Hz, H3), 7.75-7.70 (2H, m, 
AA´, BB´, H2´, H6´), 7.73 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.43-7.36 (3H, m, H6, H3´, 
H5´), 4.36 (1H, m, CH), 1.47 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  168.7, 
162.5, 146.1, 137.9, 132.0, 131.0, 130.9, 129.6, 129.3, 129.2, 128.9, 127.9, 125.3, 121.7, 48.3, 
15.8. 
(S)-1-(4-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8h. 
White solid; yield 97%; mp 202-204 °C. IR (KBr pellet): 3424, 2969, 2880, 1756 (CO ester), 
1663, 1596, 1518, 1493, 1400, 1313, 1198, 1014, 828, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.72 (1H, bs, NH), 8.51 (3H, bs, NH2.HBr), 7.83 (1H, d, J=2.4 Hz, H3), 7.74-7.70 (2H, m, 
AA´, BB´, H2´, H6´), 7.58 (1H, dd, J=8.7 Hz, J=2.4 Hz, H5), 7.43-7.39 (3H, m, H6, H3´, 
H5´), 4.20 (1H, m CH), 2.33-2.23 (1H, m, CH), 0.98 (3H, d, J=6.6 Hz, CH3), 0.96 (3H, d, 
J=6.6 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 162.7, 155.2, 145.7, 137.9, 131.7, 
131.5, 131.0, 129.1, 129.0, 128.9, 127.8, 125.2, 121.5, 57.6, 29.3, 18.0, 17.9. 
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(R)-1-(4-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8i. 
White solid; yield 92%; mp 209-211 °C. IR (KBr pellet): 3415, 2969, 1757 (CO ester), 1660, 
1595, 1493, 1399, 1314, 1291, 1198, 1103, 1014, 821, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.73 (1H, bs, NH), 8.52 (3H, bs, NH2.HBr), 7.83 (1H, d, J=2.7 Hz, H3), 7.74-7.71 (2H, m, 
AA´, BB´, H2´, H6´), 7.58 (1H, dd, J=8.1 Hz, J=2.7 Hz, H5), 7.44-7.38 (3H, m, H6, H3´, 
H5´), 4.19 (1H, m CH), 2.31-2.23 (1H, m, CH), 0.98 (3H, d, J=6.6 Hz, CH3), 0.96 (3H, d, 
J=6.6 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 162.7, 155.2, 145.8, 137.9, 131.7, 
131.5, 131. 0, 129.1, 129.0, 128.9, 127.8, 125.2, 121.5, 57.6, 29.3, 18.0, 17.9. 
 
(S)-1-(4-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8j. 
White solid; yield 92%; mp 214-216 °C. IR (KBr pellet): 3421, 1763 (CO ester), 1658, 1595, 
1493, 1400, 1204, 1102, 825, 701, 507 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.72 (1H, bs, 
NH), 8.61 (3H, bs, NH2.HBr) 7.87 (1H, d, J=2.7 Hz, H3), 7.78-7.73 (2H, m, AA´, BB´, 
overlapped, H2´, H6´), 7.73 (1H, dd, overlapped, J=8.5 Hz, J=2.7 Hz, H4), 7.45-7.39 (2H, m, 
AA´, BB´, H3´, H5´), 7.33-7.21 (6H, m, H6, H2´´, H3´´, H4´´, H5´´, H6´´), 4.54 (1H, m, CH), 
3.25 (1H, dd, J=14.4 Hz, J=6.7 Hz, CH2), 3.13 (1H, dd, J=14.4 Hz, J=6.7 Hz, CH2). 
13
C NMR 
(75 MHz, DMSO)  167.5, 162.6, 146.1, 137.9, 134.8, 132.0, 131.0, 130.8, 129.7, 129.3, 
128.9, 128.8, 127.9, 127.5, 125.2, 121.7, 53.5, 35.6. MS (ESI): m/z (%) 511.2 (M+H
+
), 25), 
210.1 (100), 127.1 (92). 
(R)-1-(4-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8k. 
White solid; yield 95%; mp 205-209 °C. IR (KBr pellet): 3409, 1763 (CO ester), 1658, 1595, 
1493, 1400, 1313, 1205, 1102, 1014, 824, 702, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.72 (1H, bs, NH), 8.61 (3H, bs, NH2.HBr) 7.87 (1H, d, J=2.7 Hz, H3), 7.77-7.72 (2H, m, 
AA´, BB´overlapped, H2´, H6´), 7.72 (1H, dd overlapped, J=8.4 Hz, J=2.7 Hz, H4), 7.43-
7.40 (2H, m, AA´, BB´, H3´, H5´), 7.31-7.24 (6H, m, H6, H2´´, H3´´, H4´´, H5´´, H6´´), 4.54 
(1H, m, CH), 3.29 (1H, dd, J=14.4 Hz, J=6.6 Hz, CH2), 3.13 (1H, dd, J=14.4 Hz, J=6.6 Hz, 
CH2). 
13
C NMR (75 MHz, DMSO)  167.5, 162.6, 146.1, 137.9, 134.8, 132.0, 131.0, 130.8, 
129.7, 129.4, 128.9, 128.8, 127.9, 127.5, 125.1, 121.7, 53.5, 35.6. 
(S)-1-(2-(4-Bromophenylcarbamoyl)-4-chlorophenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8l. 
White solid; yield 97%; mp 195-198 °C. IR (KBr pellet): 3309, 1762 (CO ester), 1662, 1591, 
1515, 1490, 1395, 1312, 1206, 1104, 1072, 1011, 918, 820, 703, 505 cm
-1
. 
1
H NMR (300 
MHz, DMSO) 10.71 (1H, bs, NH), 8.61 (3H, bs, NH2.HBr) 7.87 (1H, d, J=2.7 Hz, H3), 
7.73-7.68 (3H, m, H4, H2´, H6´), 7.38-7.23 (8H, m, H6, H3´, H5´, H2´´, H3´´, H4´´, H5´´, 
H6´´), 4.54 (1H, m, CH), 3.29 (1H, dd, J=14.4 Hz, J=6.6 Hz, CH2), 3.12 (1H, dd, J=14.4 Hz, 
J=6.6 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.5, 162.6, 155.1, 138.1, 134.8, 133.6, 
132.0, 131.9, 131.8, 131.0, 130.8, 129.5, 128.9, 128.8, 123.3, 122.1, 53.5, 28.3. 
2-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-2-oxoethanaminium bromide 8m. 
White solid; yield 69%; mp 158-162 °C. IR (KBr pellet): 3420, 1774 (CO ester), 1659, 1589, 
1522, 1477, 1389, 1207, 1105, 1029, 814 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.81 (1H, bs, 
NH), 8.42 (3H, bs, NH2.HBr), 8.09 (1H, d, J=1.5 Hz, H2´), 7.91 (1H, d, d, J=2.4 Hz, H3), 
7.75 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.58-7.57 (2H, m, H6´, H5´), 7.36 (1H, d, J=8.7 Hz, 
H6), 4.08 (2H, m, CH2). ). 
13
C NMR (75 MHz, DMSO)  166.7, 162.8, 146.4, 138.9, 132.4, 
131.1, 131.0, 130.9, 130.1, 129.5, 125.8, 125.5, 121.6, 120.4, 49.5. 
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(S)-1-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 
8n. 
White solid; yield 67%; mp 177-181 °C. IR (KBr pellet): 3425, 1774 (CO ester), 1659, 1591, 
1477, 1380, 1306, 1202, 1105, 1030, 817, 570 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.81 
(1H, bs, NH), 8.48 (3H, bs, NH2.HBr), 8.07 (1H, d, J=1.8 Hz, H2´), 7.89 (1H, d, J=2.4 Hz, 
H3), 7.75 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.62 (2H, m, H6´, H5´), 7.37 (1H, d, J=9.0 Hz, 
H6), 4.39 (1H, m, CH), 1.48 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.5, 
162.5, 155.2, 146.1, 140.3, 133.1, 132.0, 131.0, 130.7, 129.2, 125.1, 124.0, 119.5, 118.5, 48.2, 
15.7. 
(S)-1-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8o. 
White solid; yield 87%; mp 202-204 °C. IR (KBr pellet): 3293, 2969, 1756 (CO ester), 1668, 
1592, 1510, 1477, 1387, 1302, 1248, 1194, 1130, 1106, 1029, 815, 732, 576 cm
-1
. 
1
H NMR 
(300 MHz, DMSO) 10.88 (1H, bs, NH), 8.52 (3H, bs, NH2.HBr), 8.08 (1H, d, J=1.8 Hz, 
H2´), 7.86 (1H, d, J=2.4 Hz, H3), 7.74 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.62 (2H, m, H6´, 
H5´), 7.40 (1H, d, J=8.7 Hz, H6), 4.21 (1H, m, CH), 2.35-2.24 (1H, m, CH), 0.99 (3H, d, 
J=5.1 Hz, CH3), 0.97 (3H, d, J=5.1 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 163.0, 
155.4, 145.8, 139.0, 132.0, 131.2, 131.1, 131.0, 129.0, 125.7, 125.3, 121.2, 120.1, 57.6, 29.3, 
18.0, 17.9. 
(R)-1-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8p. 
White solid; yield 89%; mp 198-200 °C. IR (KBr pellet): 3494, 2969, 1756 (CO ester), 1668, 
1592, 1510, 1477, 1382, 1303, 1194, 1105, 1029, 815 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.88 (1H, bs, NH), 8.52 (3H, bs, NH2.HBr), 8.08 (1H, d, J=1.5 Hz, H2´), 7.85 (1H, d, 
J=2.7 Hz, H3), 7.74 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.61 (2H, m, H6´, H5´), 7.40 (1H, d, 
J=8.7 Hz, H6), 4.22 (1H, m, CH), 2.35-2.26 (1H, m, CH), 0.99 (3H, d, J=5.1 Hz, CH3), 0.95 
(3H, d, J=5.1 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.7, 163.0, 155.4, 145.8, 139.0, 
132.0, 131.2, 131.1, 131.0, 129.0, 125.7, 125.3, 121.2, 120.1, 57.6, 29.3, 18.0, 17.9. 
(S)-1-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8q. 
White solid; yield 90%; mp 191-193 °C. IR (KBr pellet): 3417, 1761 (CO ester), 1663, 1585, 
1476, 1378, 1305, 1206, 1105, 1031, 813, 702 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.86 
(1H, bs, NH), 8.61 (3H, bs, NH2.HBr), 8.11 (1H, d, J=1.2 Hz, H2´), 7.83 (1H, d, J=2.6 Hz, 
H3), 7.85 (1H, d, J=6.2 Hz, H5´), 7.78 (1H, d, J=8.7 Hz, H6), 7.74 (1H, dd, J=6.4 Hz, J=1.3 
Hz, H6´), 7.42 (1H, dd, J=8.7 Hz, J=2.5 Hz, H5), 7.37-7.36 (5H, m, H2´´, H3´´, H4´´, H5´´, 
H6´´), 4.52 (1H, m, CH), 3.29 (1H, dd, J=14.0 Hz, J=6.9 Hz, CH2), 3.14 (1H, dd, J=14.0 Hz, 
J=6.9 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.5, 162.9, 154.9, 142.3, 139.0, 133.9, 
133.0, 132.4, 131.6, 131.4, 131.2, 131.1, 130.4, 129.7, 129.6, 129.4, 128.9, 127.0, 122.6, 
118.1, 53.8, 28.3. 
(R)-1-(4-Chloro-2-(3,4-dichlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-
aminium bromide 8r. 
White solid; yield 90%; mp 200-203 °C. IR (KBr pellet): 3420, 1762 (CO ester), 1663, 1585, 
1476, 1377, 1305, 1206, 1105, 1031, 703 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.85 (1H, bs, 
NH), 8.61 (3H, bs, NH2.HBr), 8.10 (1H, d, J=1.3 Hz, H2´), 7.85 (1H, d, J=2.7 Hz, H3), 7.87 
(1H, d, J=6.4 Hz, H5´), 7.80 (1H, d, J=8.7 Hz, H6), 7.75 (1H, dd, J=6.5 Hz, J=1.1 Hz, H6´), 
7.42 (1H, dd, J=8.7 Hz, J=2.7 Hz, H5), 7.37-7.36 (5H, m, H2´´, H3´´, H4´´, H5´´, H6´´), 4.52 
(1H, m, CH), 3.29 (1H, dd, J=14.0 Hz, J=7.0 Hz, CH2), 3.14 (1H, dd, J=14.0 Hz, J=7.0 Hz, 
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CH2). 
13
C NMR (75 MHz, DMSO)  167.5, 162.9, 154.9, 142.3, 139.0, 136.0, 133.9, 132.9, 
131.8, 131.6, 131.3, 131.1, 130.8, 129.9, 129.6, 129.5, 128.9, 127.5, 122.8, 118.3, 53.5, 28.4. 
(S)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 8s. 
White solid; yield 85%; mp 185-187 °C. IR (KBr pellet): 3416, 2884, 1773 (CO ester), 1654, 
1596, 1522, 1493, 1400, 1314, 1200, 1176, 1105, 1096, 1013, 906, 879, 827, 508 cm
-1
. 
1
H 
NMR (300 MHz, DMSO) 10.64 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.81 (1H, d, J=8.1 
Hz, H3), 7.75-7.71 (2H, m, AA´, BB´, H2´, H6´), 7.61-7.56 (2H, m, AA´, BB´, H3´, H5´), 
7.42-7.39 (2H, m, H4, H6), 4.36 (1H, m, CH), 1.48 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 
MHz, DMSO)  168.5, 163.0, 157.1, 148.0, 141.7, 137.9, 134.7, 129.6, 129.1, 129.0, 128.8, 
127.1, 124.3, 121.8, 48.3, 15.7. 
(R)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 8t. 
White solid; yield 83%; mp 178-181 °C. IR (KBr pellet): 3420, 2887, 1781 (CO ester), 1653, 
1596, 1526, 1493, 1400, 1315, 1201, 1177, 1105, 1096, 1014, 906, 827, 508 cm
-1
. 
1
H NMR 
(300 MHz, DMSO) 10.64 (1H, bs, NH), 8.51 (3H, bs, NH2.HBr), 7.81 (1H, d, J=8.4 Hz, 
H3), 7.74-7.71 (2H, m, AA´, BB´, H2´, H6´), 7.61-7.56 (2H, m, AA´, BB´, H3´, H5´), 7.42-
7.39 (2H, m, H4, H6), 4.36 (1H, m, CH), 1.48 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, 
DMSO)  168.6, 163.0, 157.3, 148.0, 142.0, 137.9, 135.8, 131.1, 128.9, 128.3, 127.8, 123.5, 
121.7, 119.9, 48.3, 15.7. 
(S)-1-(5-Chloro-2-(4-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8u. 
White solid; yield 92%; mp 201-204 °C. IR (KBr pellet): 3422, 3294, 2969, 1759 (CO ester), 
1662, 1595, 1515, 1493, 1399, 1312, 1196, 1095, 1014, 910, 827, 508 cm
-1
. 
1
H NMR (300 
MHz, DMSO) 10.68 (1H, bs, NH), 8.52 (3H, bs, NH2.HBr), 7.75 (1H, d, J=8.1 Hz, H3), 
7.75-7.71 (2H, m, AA´, BB´, H2´, H6´), 7.60-7.55 (2H, m, AA´, BB´, H3´, H5´), 7.40-7.33 
(2H, m, H4, H6), 4.15 (1H, m, CH), 2.32-2.25 (1H, m, CH), 0.98 (3H, d, J=5.2 Hz, CH3), 
0.96 (3H, d, J=5.2 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  167.6, 163.2, 155.7, 147.7, 138.0, 
135.5, 130.8, 129.2, 128.9, 128.9, 127.8, 127.1, 123.5, 121.5, 57.7, 29.3, 18.0, 17.9. 
2-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-2-oxoethanaminium bromide 8v. 
White solid; yield 45%; mp 162-165 °C. IR (KBr pellet): 3420, 1771 (CO ester), 1654, 1594, 
1533, 1481, 1424, 1391, 1312, 1211, 1106, 899, 780, 531 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.70 (1H, bs, NH), 8.42 (3H, bs, NH2.HBr), 7.90 (2H, m, H3, H2´), 7.75 (1H, dd, J=8.7 
Hz, J=2.7 Hz, H5), 7.58-7.57 (2H, m, H6´, H4´), 7.50 (1H, d, J=8.7 Hz, H6), 7.36 (1H, dd, 
J=7.8 Hz, J=2.7 Hz, H5´), 4.08 (2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  167.9, 162.8, 
157.9, 144.8, 140.3, 144.8, 140.3, 133.5, 133.2, 131.2, 130.6, 130.3, 125.7, 125.5, 49.4. 
(S)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 8w. 
White solid; yield 90%; mp 182-185 °C. IR (KBr pellet): 3286, 2935, 1775 (CO ester), 1663, 
1593, 1525, 1481, 1424, 1391, 1311, 1203, 1107, 999, 928, 876, 781, 728, 680, 532 cm
-1
. 
1
H 
NMR (300 MHz, DMSO) 10.72 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.89 (1H, t, J=1.8 
Hz, H2´), 7.86 (1H, d, J=2.7 Hz, H3), 7.74 (1H, dd, J=8.9 Hz, J=2.7 Hz, H5), 7.50 (1H, d, 
J=9.0 Hz, H6), 7.41-7.30 (2H, m, H6´, H4´), 7.18 (1H, dd, J=7.8 Hz, J=1.2 Hz, H5´), 4.40 
(1H, m, CH), 1.48 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  168.7, 162.7, 
155.2, 146.1, 140.3, 133.8, 134.7, 131.8, 131.2, 131.1, 131.0, 129.6, 124.0, 118.0, 48.2, 15.8. 
(R)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-1-oxopropan-2-aminium bromide 8x. 
White solid; yield 90%; mp 177-183 °C. IR (KBr pellet): 3286, 2935, 1775 (CO ester), 1663, 
1594, 1521, 1481, 1424, 1311, 1203, 1106, 876, 776, 678, 532 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 10.72 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.88 (1H, t, J=1.9 Hz, H2´), 7.86 (1H, 
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d, J=2.5 Hz, H3), 7.74 (1H, dd, J=8.8 Hz, J=2.5 Hz, H5), 7.50 (1H, d, J=8.9 Hz, H6), 7.41-
7.30 (2H, m, H6´, H4´), 7.18 (1H, dd, J=7.8 Hz, J=0.9 Hz, H5´), 4.40 (1H, m, CH), 1.48 (3H, 
d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, DMSO)  168.7, 162.7, 155.2, 146.1, 140.3, 133.2, 
132.1, 131.0, 130.7, 129.3, 125.2, 124.0, 119.6, 118.5, 48.2, 15.7. 
(S)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8y. 
White solid; yield 88%; mp 199-202 °C. IR (KBr pellet): 3420, 2969, 1765 (CO ester), 1668, 
1593, 1515, 1483, 1422, 1298, 1199, 1107, 777, 677, 539 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.77 (1H, bs, NH), 8.54 (3H, bs, NH2.HBr), 7.90 (1H, t, J=1.8 Hz, H2´), 7.85 (1H, d, J=2.7 
Hz, H3), 7.73 (1H, dd, J=8.7 Hz, J=2.5 Hz, H5), 7.57 (1H, d, J=8.7 Hz, H6), 7.42-7.35 (2H, 
m, H6´, H4´), 7.17 (1H, dd, J=8.0 Hz, J=0.9 Hz, H5´), 4.21 (1H, m, CH), 2.35-2.24 (1H, m, 
CH), 0.99 (3H, d, J=6.5 Hz, CH3), 0.97 (3H, d, J=6.5 Hz, CH3). 
13
C NMR (75 MHz, DMSO) 
 167.7, 162.9, 155.3, 145.8, 140.4, 133.2, 131.8, 131.0, 130.7, 129.0, 125.3, 124.0, 119.4, 
118.4, 57.6, 29.3, 18.0, 17.9. 
(R)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-3-methyl-1-oxobutan-2-aminium 
bromide 8z. 
White solid; yield 77%; mp 187-189 °C. IR (KBr pellet): 3317, 2969, 1765 (CO ester), 1668, 
1593, 1515, 1483, 1422, 1299, 1199, 1107, 777, 677, 540 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
10.77 (1H, bs, NH), 8.50 (3H, bs, NH2.HBr), 7.89 (1H, t, J=2.1 Hz, H2´), 7.85 (1H, d, J=2.7 
Hz, H3), 7.73 (1H, dd, J=9.0 Hz, J=2.5 Hz, H5), 7.55 (1H, d, J=8.7 Hz, H6), 7.40-7.37 (2H, 
m, H6´, H4´), 7.17 (1H, dd, J=8.1 Hz, J=1.2 Hz, H5´), 4.22 (1H, m, CH), 2.35-2.24 (1H, m, 
CH), 0.99 (3H, d, J=6.6 Hz, CH3), 0.97 (3H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, DMSO) 
 167.7, 163.0, 155.3, 145.8, 140.4, 133.2, 131.4, 131.1, 130.7, 130.0, 125.2, 124.0, 119.4, 
118.4, 57.6, 29.3, 18.0, 17.9. 
(S)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8aa. 
White solid; yield 96%; mp 195-197 °C. IR (KBr pellet): 2858, 1762 (CO ester), 1661, 1593, 
1529, 1482, 1424, 1309, 1206, 1106, 879, 678 cm
-1
. 
1
H NMR (300 MHz, DMSO) 10.77 
(1H, bs, NH), 8.66 (3H, bs, NH2.HBr), 7.94 (1H, t, J=1.8 Hz, H2´), 7.88 (1H, d, J=2.7 Hz, 
H3), 7.74 (1H, dd, J=8.7 Hz, J=2.4 Hz, H5), 7.61 (1H, d, J=8.6 Hz, H6), 7.39 (1H, t, J=8.1 
Hz, H5´), 7.33-7.30 (3H, m, H6´, H4´, H4´´), 7.25-7.16 (4H, m, H2´´, H3´´, H5´´, H6´´), 4.57 
(1H, m, CH), 3.30 (1H, dd, J=14.4 Hz, J=6.9 Hz, CH2), 3.16 (1H, dd, J=14.4 Hz, J=6.9 Hz, 
CH2). 
13
C NMR (75 MHz, DMSO)  170.1, 166.4, 157.6, 140.3, 137.4, 133.5, 133.3, 130.7, 
129.4, 128.6, 128.5, 126.8, 123.5, 122.9, 119.4, 119.1, 118.0, 117.7, 55.6, 37.5. 
(R)-1-(4-Chloro-2-(3-chlorophenylcarbamoyl)phenoxy)-1-oxo-3-phenylpropan-2-aminium 
bromide 8bb. 
White solid; yield 89%; mp 188-192 °C. IR (KBr pellet): 3424, 2962, 1762 (CO ester), 1661, 
1594, 1527, 1482, 1424, 1310, 1205, 1107, 1080, 880, 783, 701 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 10.76 (1H, bs, NH), 8.62 (3H, bs, NH2.HBr), 7.93 (1H, t, J=2.1 Hz, H2´), 7.88 (1H, 
d, J=2.4 Hz, H3), 7.74 (1H, dd, J=8.5 Hz, J=2.4 Hz, H5), 7.60 (1H, d, J=8.4 Hz, H6), 7.37 
(1H, t, J=8.1 Hz, H5´), 7.33-7.29 (3H, m, H6´, H4´, H4´´), 7.27-7.16 (4H, m, H2´´, H3´´, 
H5´´, H6´´), 4.57 (1H, m, CH), 3.30 (1H, dd, J=14.1 Hz, J=6.6 Hz, CH2), 3.16 (1H, dd, 
J=14.1 Hz, J=6.6 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.4, 162.8, 149.9, 146.1, 140.4, 
134.8, 133.2, 132.1, 131.0, 130.7, 129.7, 129.4, 128.8, 127.5, 125.2, 124.0, 119.7, 118.6, 53.5, 
35.7. 
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5.1.2. Hydroxy-N-(phenylamino)-oxo-alkyl benzamides 9. 
General procedure  
Triethylamine (0.95 mmol) was added to a stirred suspension of hydrobromide salt 8 (1 
mmol) in dry chloroform (10 ml) at room temperature. After 30 min of stirring, an insoluble 
material was filtered off and the filtrate was purified by using a Chromatotron® Harrison 
Research Model 7924T (toluene/ethyl acetate 4:1) or flash chromatography (toluene/ethyl 
acetate 9:1). Hydroxy-N-(phenylamino)-oxo-alkyl benzamides 9 were isolated as unexpected 
products of amino group liberation. 
Data of prepared hydroxy-N-(phenylamino)-oxo-alkyl benzamides 9 
(S)-N-(1-(4-Bromophenylamino)-3-methyl-1-oxobutan-2-yl)-5-chloro-2-hydroxybenzamide 
9a. 
White solid; yield 56%; mp 226-228 °C. IR (KBr pellet): 3297, 2966, 1668, 1634, 1604, 
1538, 1489, 1398, 1288, 1245, 1114, 1074, 1010, 823, 651 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.02 (1H, s, NH), 10.38 (1H, bs, OH), 8.94 (1H, d, J=8.1 Hz, NH), 8.00 (1H, dd, J=2.4 Hz, 
J=0.9 Hz, H6), 7.60-7.57 (2H, m, AA´, BB´, H2´, H6´), 7.50-7.47 (2H, m, AA´, BB´, H3´, 
H5´), 7.43 (1H, ddd, J=9.0 Hz, J=3.0 Hz, J=0.9 Hz, H4 ), 6.97 (1H, dd, J=9.0 Hz, J=1.2 Hz, 
H3), 4.53 (1H, t, J=7.5 Hz, CH), 2.22-2.11 (1H, m, CH), 0.95 (6H, d, J=6.9 Hz, CH3). 
13
C 
NMR (75 MHz, CDCl3)  170.1, 165.7, 156.9, 138.2, 133.2, 131.8, 129.1, 123.0, 121.54, 
119.2, 118.6, 115.3, 59.3, 30.9, 19.4, 18.6. Anal. Calcd for C18H18BrClN2O3 (425.70): C, 
50.78; H, 4.26; N, 6.58. Found: C, 50.825; H, 4.435; N, 6.48. 
(R)-N-(1-(4-Bromophenylamino)-3-methyl-1-oxobutan-2-yl)-5-chloro-2-hydroxybenzamide 
9b. 
White solid; yield 50%; mp 214-216 °C. IR (KBr pellet): 3298, 2968, 1668, 1633, 1595, 
1537, 1489, 1398, 1286, 1249, 1073, 1011, 817, 648, 505 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.02 (1H, s, NH), 10.38 (1H, bs, OH), 8.94 (1H, d, J=8.1 Hz, NH), 8.00 (1H, d, J=2.7 Hz, 
H6), 7.60-7.57 (2H, m, AA´, BB´, H2´, H6´), 7.50-7.47 (2H, m, AA´, BB´, H3´, H5´), 7.43 
(1H, ddd, J=9.0 Hz, J=2.7 Hz, J=0.6 Hz, H4 ), 6.97 (1H, d, J=9.0 Hz, H3), 4.53 (1H, t, J=7.8 
Hz, CH), 2.22-2.11 (1H, m, CH), 0.95 (6H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  
170.1, 165.7, 156.9, 138.2, 133.2, 131.8, 129.1, 123.1, 121.5, 119.2, 118.6, 115.4, 59.3, 31.0, 
19.4, 18.6. Anal. Calcd for C18H18BrClN2O3 (425.70): C, 50.78; H, 4.26; N, 6.58. Found: C, 
51.05; H, 4.40; N, 6.425. 
(R)-N-(1-(4-Bromophenylamino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide 
9c. 
White solid; yield 32%; mp 239-242 °C. IR (KBr pellet): 3370, 3269, 1675, 1628, 1601, 
1591, 1530, 1488, 1397, 1281, 1246, 1230, 1114, 1072, 1010, 825, 746, 700, 651, 536 cm
-1
. 
1
H NMR (300 MHz, DMSO) 12.06 (1H, bs, NH), 10.40 (1H, s, OH), 9.11 (1H, d, J=7.5 Hz, 
NH), 7.98 (1H, m, H6), 7.58-7.53 (2H, m, AA´, BB´, H2´, H6´), 7.51-7.48 (2H, m, AA´, BB´, 
H3´, H5´), 7.42 (1H, ddd, J=8.7 Hz, J=2.4 Hz, J=0.6 Hz, H4 ), 7.31-7.16 (5H, m, H2´´, H3´´, 
H4´´, H5´´, H6´´), 6.93 (1H, dd, J=8.7 Hz, J=0.6 Hz, H3), 4.93-4.86 (1H, m, CH), 3.22-3.05 
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(2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  169.9, 166.3, 157.7, 138.2, 137.4, 133.5, 131.8, 
129.4, 128.5, 128.4, 126.8, 122.8, 121.6, 119.4, 117.7, 115.4, 55.5, 37.6. Anal. Calcd for 
C22H18 BrClN2O3 (473.75): C, 55.78; H, 3.83; N, 5.91. Found: C, 55.52; H, 3.92; N, 5.86. 
(R)-4-Chloro-N-(1-(4-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 
9d. 
White solid; yield 48%; mp 204-205 °C. IR (KBr pellet): 3304, 2966, 1669, 1635, 1598, 
1541, 1492, 1403, 1349, 1299, 1241, 1216, 1092, 1013, 916, 827, 768, 508 cm
-1
. 
1
H NMR 
(300 MHz, DMSO) 12.23 (1H, s, NH), 10.38 (1H, bs, OH), 8. 85 (1H, d, J=8.1 Hz, NH), 
7.99 (1H, d, J=9.0 Hz, H6), 7.65-7.62 (2H, m, AA´, BB´, H2´, H6´), 7.37-7.34 (2H, m, AA´, 
BB´, H3´, H5´), 7.00-6.97 (2H, m, H3, H5), 4.53 (1H, t, J=7.5 Hz, CH), 2.22-2.11 (1H, m, 
CH), 0.95 (6H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  170.2, 166.1, 158.8, 137.8, 
137.4, 131.6, 128.8, 127.3, 121.1, 119.6, 116.7, 116.3, 59.2, 30.9, 19.4, 18.6. Anal. Calcd for 
C18H18Cl2N2O3 (381.25): C, 56.71; H, 4.76; N, 7.35. Found: C, 56.99; H, 4.99; N, 7.30. 
(S)-4-Chloro-N-(1-(4-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9e. 
White solid; yield 40%; mp 232-234 °C. IR (KBr pellet): 3376, 3270, 1676, 1637, 1597, 
1534, 1492, 1402, 1299, 1232, 1092, 1014, 918, 862, 825, 744, 700, 572 cm
-1
. 
1
H NMR (300 
MHz, DMSO)  (1H, bs, NH), 10.40 (1H, s, OH), 9.03 (1H, d, J=7.5 Hz, NH), 7.94 
(1H, d, J=8.4 Hz, H6), 7.63-7.59 (2H, m, AA´, BB´, H2´, H6´), 7.39-7.35 (2H, m, AA´, BB´, 
H3´, H5´), 7.38-7.15 (5H, m, H5, H3, H2´´, H4´´, H6´´), 7.00-6.96 (2H, m, H3´´, H5´´), 4.92-
4.84 (1H, m, CH), 3.21-3.05 (2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  170.0, 166.8, 
159.7, 137.8, 137.5, 131.0, 129.4, 128.9, 128.4, 127.5, 127.4, 126.8, 121.2, 119.4, 117.0, 
115.4, 55.5, 37.6. Anal. Calcd for C22H18Cl2N2O3 (429.30): C, 61.55; H, 4.23; N, 6.53. Found: 
C, 61.30; H, 4.435; N, 6.475. 
(R)-4-Chloro-N-(1-(4-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9f. 
White solid; yield 40%; mp 232-234 °C. IR (KBr pellet): 3377, 3266, 1677, 1599, 1532, 
1492, 1402, 1299, 1233, 1091, 1014, 918, 825, 744, 700, 571, 496 cm
-1
. 
1
H NMR (300 MHz, 
DMSO)  (1H, bs, NH), 10.40 (1H, s, OH), 9.00 (1H, d, J=7.3 Hz, NH), 7.94 (1H, d, 
J=8.7 Hz, H6), 7.63-7.59 (2H, m, AA´, BB´, H2´, H6´), 7.39-7.35 (2H, m, AA´, BB´, H3´, 
H5´), 7.37-7.17 (5H, m, H5, H3, H2´´, H4´´, H6´´), 7.05-6.99 (2H, m, H3´´, H5´´), 4.90-4.81 
(1H, m, CH), 3.20-3.06 (2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  170.0, 166.9, 159.7, 
137.8, 137.7, 137.5, 129.4, 128.9, 128.4, 128.5, 127.3, 126.8, 121.2, 119.4, 117.0, 115.4, 55.5, 
37.6. Anal. Calcd for C22H18Cl2N2O3 (429.30): C, 61.55; H, 4.23; N, 6.53. Found: C, 60.57; 
H, 4.43; N, 6.46. 
(R)-5-Chloro-N-(1-(4-chlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9g. 
White solid; yield 49%; mp 241-243 °C. IR (KBr pellet): 3368, 1683, 1628, 1601, 1534, 
1493, 1401, 1301, 1288, 1094, 1015, 825, 650, 508 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.20 (1H, s, NH), 10.30 (1H, bs, OH), 9.09 (1H, d, J=6.6 Hz, NH), 8.04 (1H, d, J=2.2 Hz, 
H6), 7.65-7.62 (2H, m, AA´, BB´, H2´, H6´), 7.43 (1H, dd, J=8.7 Hz, J=2.2 Hz, H4 ), 7.37-
7.34 (2H, m, AA´, BB´, H3´, H5´), 6.96 (1H, d, J=8.7 Hz, H3), 4.63 (1H, m CH), 1.44 (3H, d, 
J=6.9 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  171.1, 166.5, 157.9, 138.0, 133.5, 128.9, 
128.5, 127.2, 122.8, 121.1, 119.4, 117.5, 49.9, 18.3. Anal. Calcd for C16H14Cl2N2O3 (353.20): 
C, 54.41; H, 4.00; N, 7.93. Found: C, 54.695; H, 3.875; N, 7.94. 
(S)-5-Chloro-N-(1-(4-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 
9h. 
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White solid; yield 39%; mp 202-205 °C. IR (KBr pellet): 3297, 2966, 1672, 1645, 1630, 
1598, 1492, 1401, 1235, 1114, 1090, 1014, 827, 651 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.03 (1H, s, NH), 10.38 (1H, bs, OH), 8.95 (1H, d, J=8.1 Hz, NH), 8.00 (1H, d, J=2.7 Hz, 
H6), 7.65-7.62 (2H, m, AA´, BB´, H2´, H6´), 7.43 (1H, dd, J=9.0 Hz, J=2.7 Hz, H4 ), 7.37-
7.34 (2H, m, AA´, BB´, H3´, H5´), 6.97 (1H, d, J=9.0 Hz, H3), 4.53 (1H, t, J=7.8 Hz, CH), 
2.22-2.09 (1H, m, CH), 0.95 (6H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  170.1, 
165.7, 156.9, 137.8, 133.2, 129.2, 128.9, 127.3, 123.0, 121.1, 119.3, 118.6, 59.3, 31.0, 19.4, 
18.6. MS (EI+): m/z (%) 380.8 (M
+
, 12), 254.1 (100), 225.9 (65), 127.0 (88). Anal. Calcd for 
C18H18Cl2N2O3 (381.2): C, 56.71; H, 4.76; N, 7.35. Found: C, 56.925; H, 4.91; N, 7.40. 
(R)-5-Chloro-N-(1-(4-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 
9i. 
White solid; yield 57%; mp 214-216 °C. IR (KBr pellet): 3297, 2966, 1668, 1634, 1599, 
1534, 1493, 1403, 1288, 1246, 1093, 1014, 825, 650 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.04 (1H, s, NH), 10.38 (1H, bs, OH), 8.95 (1H, d, J=8.1 Hz, NH), 8.00 (1H, dd, J=2.4 Hz, 
J=0.9 Hz, H6), 7.65-7.62 (2H, m, AA´, BB´, H2´, H6´), 7.43 (1H, ddd, J=8.8 Hz, J=2.7 Hz, 
J=1.2 Hz, H4 ), 7.37-7.34 (2H, m, AA´, BB´, H3´, H5´), 6.97 (1H, dd, J=8.8 Hz, J=1.2 Hz, 
H3), 4.53 (1H, t, J=7.8 Hz, CH), 2.20-2.13 (1H, m, CH), 0.96 (6H, d, J=6.6 Hz, CH3). 
13
C 
NMR (75 MHz, CDCl3)  171.3, 167.7, 157.5, 135.7, 133.8, 129.0, 128.9, 125.3, 124.5, 
121.1, 119.0, 116.5, 60.8, 31.0, 19.4, 19.0. Anal. Calcd for C18H18Cl2N2O3 (381.25): C, 56.71; 
H, 4.76; N, 7.35. Found: C, 56.77; H, 4.745; N, 7.365. 
(S)-5-Chloro-N-(1-(4-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9j. 
White solid; yield 44%; mp 236-238 °C. IR (KBr pellet): 3370, 3262, 1671, 1649, 1627, 
1536, 1492, 1455, 1401, 1282, 1230, 1091, 1014, 914, 821, 746, 698, 670, 650, 534, 507 cm
-1
. 
1
H NMR (300 MHz, DMSO)  (1H, bs, NH), 10.41 (1H, s, OH), 9.11 (1H, d, J=7.5 Hz, 
NH), 7.97 (1H, d, J=2.5 Hz, H6), 7.65-7.60 (2H, m, AA´, BB´, H2´, H6´), 7.43 (1H, dd, J=8.7 
Hz, J=2.4 Hz, H4 ), 7.39-7.34 (2H, m, AA´, BB´, H3´, H5´), 7.32-7.18 (5H, m, H2´´, H3´´, 
H4´´, H5´´, H6´´), 6.93 (1H, d, J=8.7 Hz, H3), 4.90-4.85 (1H, m, CH), 3.20-3.04 (2H, m, 
CH2). 
13
C NMR (75 MHz, DMSO)  169.9, 166.3, 157.6, 137.8, 137.5, 133.5, 129.4, 128.9, 
128.6, 128.5, 127.4, 126.8, 122.9, 121.2, 119.4, 117.7, 55.5, 37.6. Anal. Calcd for 
C22H18Cl2N2O3 (429.30): C, 61.55; H, 4.23; N, 6.53. Found: C, 61.205; H, 4.62; N, 6.515. 
(R)-5-Chloro-N-(1-(4-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9k. 
White solid; yield 61%; mp 236-238 °C. IR (KBr pellet): 3372, 3260, 1669, 1647, 1626, 
1535, 1492, 1450, 1400, 1283, 1090, 1015, 746, 700, 668, 648, 530, 505 cm
-1
. 
1
H NMR (300 
MHz, DMSO)  (1H, bs, NH), 10.40 (1H, s, OH), 9.10 (1H, d, J=7.5 Hz, NH), 7.97 
(1H, d, J=2.7 Hz, H6), 7.63-7.59 (2H, m, AA´, BB´, H2´, H6´), 7.42 (1H, dd, J=8.7 Hz, J=2.7 
Hz, H4), 7.38-7.35 (2H, m, AA´, BB´, H3´, H5´), 7.32-7.18 (5H, m, H2´´, H3´´, H4´´, H5´´, 
H6´´), 6.93 (1H, d, J=8.7 Hz, H3), 4.93-4.86 (1H, m, CH), 3.22-3.04 (2H, m, CH2). 
13
C NMR 
(75 MHz, DMSO)  169.9, 166.3, 157.6, 137.8, 137.4, 133.5, 129.4, 128.9, 128.5, 128.4, 
127.4, 126.8, 122.8, 121.2, 119.4, 117.7, 55.5, 37.6. Anal. Calcd for C22H18Cl2N2O3 (429.30): 
C, 61.55; H, 4.23; N, 6.53. Found: C, 61.17; H, 4.525; N, 6.58. 
(S)-N-(1-(4-Bromophenylamino)-1-oxo-3-phenylpropan-2-yl)-5-chloro-2-hydroxybenzamide 
9l. 
White solid; yield 39%; mp 238-240 °C. IR (KBr pellet): 3371, 3266, 1684, 1647, 1627, 
1603, 1544, 1530, 1489, 1397, 1284, 1230, 1115, 1071, 1011, 819, 748, 697, 652, 585, 532, 
503 cm
-1
. 
1
H NMR (300 MHz, DMSO) 12.04 (1H, bs, NH), 10.39 (1H, s, OH), 9.09 (1H, d, 
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J=7.4 Hz, NH), 7.99-7.96 (1H, m, H6), 7.60-7.53 (2H, m, AA´, BB´, H2´, H6´), 7.52-7.46 
(2H, m, AA´, BB´, H3´, H5´), 7.42 (1H, ddd, J=8.8 Hz, J=2.5 Hz, J=0.7 Hz, H4), 7.34-7.22 
(1H, m, H4´´), 7.22-7.13 (4H, m, H2´´, H3´´, H5´´, H6´´), 6.93 (1H, dd, J=8.8 Hz, J=0.6 Hz, 
H3), 4.95-4.84 (1H, m, CH), 3.24-3.02 (2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  169.9, 
166.3, 157.6, 138.2, 137.4, 133.5, 131.8, 129.4, 128.5, 128.4, 126.8, 122.8, 121.6, 119.4, 
117.7, 115.4, 55.5, 37.6. Anal. Calcd for C22H18BrClN2O3 (473.75): C, 55.78; H, 3.83; N, 
5.91. Found: C, 55.835; H, 3.90; N, 5.885. 
5-Chloro-N-(2-(3,4-dichlorophenylamino)-2-oxoethyl)-2-hydroxybenzamide 9m. 
White solid; yield 27%; mp 232-233 °C. IR (KBr pellet): 3346, 1693, 1636, 1593, 1532, 
1475, 1395, 1286, 1230, 1130, 1031, 871, 824, 650, 535 cm
-1
.
1
H NMR (300 MHz, DMSO) 
12.16 (1H, bs, NH), 10.42 (1H, bs, OH), 9.22 (1H, t, J=5.4 Hz, NH), 7.97 (1H, d, J=2.1 Hz, 
Ar-phenyl), 7.95 (1H, d, J=2.7 Hz, Ar-phenyl), 7.58-7.43 (3H, m, H4, H5´, H6´), 6.98 (1H, d, 
J=8.7 Hz, H3), 4.13 (2H, d, J=5.4 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.9, 167.2, 
157.9, 139.0, 133.5, 131.2, 131.0, 128.3, 125.0, 122.8, 120.6, 119.5, 119.4, 117.6, 45.9. Anal. 
Calcd for C15H11Cl3N2O3 (373.62): C, 48.22; H, 2.97; N, 7.50; Cl, 28.47; O, 12.85. Found: C, 
48.17; H, 2.77; N, 7.395. 
(S)-5-Chloro-N-(1-(3,4-dichlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9n. 
White solid; yield 23%; mp 240-242 °C. IR (KBr pellet): 3347, 3277, 1664, 1635, 1589, 
1541, 1525, 1473, 1394, 1342, 1285, 1219, 1136, 1029, 897, 860, 828, 811, 694, 573 cm
-1
. 
1
H 
NMR (300 MHz, DMSO) 12.20 (1H, s, NH), 10.44 (1H, bs, OH), 8.95 (1H, d, J=6.6 Hz, 
NH), 8.04 (1H, d, J=2.7 Hz, Ar), 7.99 (1H, d, J=2.1 Hz, Ar), 7.70 (1H, d, J=8.8 Hz, Ar), 7.51 
(1H, dd, J=8.8 Hz, J=2.2 Hz, Ar), 7.44 (1H, dd, J=9.0 Hz, J=2.7 Hz, Ar), 6.96 (1H, d, J=8.7 
Hz, Ar), 4.65-4.56 (1H, m, CH), 1.44 (3H, d, J=7.3 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  
171.5, 166.7, 158.0, 139.1, 133.5, 131.2, 131.0, 128.5, 125.1, 122.8, 120,7, 119.6, 119.4, 
117.4, 50.0, 18.1. Anal. Calcd for C16H13Cl3N2O3 (387.65): C, 49.57; H, 3.38; N, 7.23. Found: 
C, 49.20; H, 3.675; N, 7.11. 
(S)-5-Chloro-N-(1-(3,4-dichlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-
hydroxybenzamide 9o. 
White solid; yield 53%; mp 201-202 °C. IR (KBr pellet): 3305, 2966, 1672, 1634, 1592, 
1532, 1476, 1393, 1289, 1232, 1134, 1114, 1029, 872, 822, 650, 533 cm
-1
. 
1
H NMR (300 
MHz, DMSO) 12.02 (1H, s, NH), 10.55 (1H, bs, OH), 8.95 (1H, d, J=8.0 Hz, NH), 8.01 
(1H, d, J=2.2 Hz, Ar), 7.99 (1H, d, J=2.8 Hz, Ar), 7.57 (1H, d, J=8.8 Hz, Ar), 7.50 (1H, dd, 
J=8.8 Hz, J=2.2 Hz, Ar), 7.43 (1H, dd, J=8.8 Hz, J=2.8 Hz, Ar), 6.97 (1H, d, J=8.8 Hz, Ar), 
4.51 (1H, t, J=7.6 Hz, CH), 2.25-2.09 (1H, m, CH), 0.95 (6H, d, J=6.6 Hz, CH3). 
13
C NMR 
(75 MHz, CDCl3)  170.5, 165.7, 156.9, 138.9, 133.3, 131.3, 131.0, 129.2, 125.2, 123.0, 
120.7, 119.6, 119.3, 118.6, 59.4, 30.9, 19.4, 18.6. Anal. Calcd for C18H17Cl3N2O3 (415.70): C, 
52.01; H, 4.12; N, 6.74. Found: C, 52.015; H, 4.925; N, 7.215. 
(R)-5-Chloro-N-(1-(3,4-dichlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-
hydroxybenzamide 9p. 
White solid; yield 40%; mp 201-203 °C. IR (KBr pellet): 3304, 2966, 1672, 1634, 1592, 
1532, 1476, 1393, 1289, 1232, 1134, 1114, 1030, 871, 821, 650, 533 cm
-1
.
1
H NMR (300 
MHz, DMSO) 12.03 (1H, s, NH), 10.55 (1H, bs, OH), 8.95 (1H, d, J=8.0 Hz, NH), 8.01 
(1H, d, J=2.2 Hz, Ar), 7.99 (1H, d, J=2.8 Hz, Ar), 7.57 (1H, d, J=9.0 Hz, Ar), 7.52 (1H, dd, 
J=9.0 Hz, J=2.4 Hz, Ar), 7.43 (1H, dd, J=8.7 Hz, J=2.7 Hz, Ar), 6.98 (1H, d, J=9.0 Hz, Ar), 
4.51 (1H, t, J=7.5 Hz, CH), 2.23-2.12 (1H, m, CH), 0.96 (6H, d, J=6.9 Hz, CH3). 
13
C NMR 
(75 MHz, CDCl3)  170.5, 165.7, 156.9, 138.8, 133.5, 131.3, 131.0, 129.2, 125.2, 123.0, 
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120.7, 119.6, 119.3, 118.6, 59.4, 30.9, 19.4, 18.6. Anal. Calcd for C18H17Cl3N2O3 (415.70): C, 
52.01; H, 4.12; N, 6.74. Found: C, 51.65; H, 4.275; N, 6.59. 
(S)-5-Chloro-N-(1-(3,4-dichlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-
hydroxybenzamide 9q. 
White solid; yield 23%; mp 240-242 °C. IR (KBr pellet): 3398, 1674, 1633, 1593, 1532, 
1476, 1455, 1417, 1375, 1289, 1232, 1134, 1118, 1030, 871, 824, 699, 650, 534 cm
-1
. 
1
H 
NMR (300 MHz, DMSO) 12.01 (1H, bs, NH), 10.56 (1H, bs, OH), 9.09 (1H, d, J=7.5 Hz, 
NH), 7.97 (2H, m, H6, H2´), 7.58 (1H, d, J=8.7 Hz, H5´), 7.49 (1H, dd, J=8.7 Hz, J=2.1 Hz, 
H6´), 7.42 (1H, ddd, J=9.0 Hz, J=2.6 Hz, J=0.9 Hz, H4), 7.31-7.24 (4H, m, H2´´, H3´´, H4´´, 
H5´´, H6´´), 7.21-7.16 (1H, m, H4´´), 6.94 (1H, dd, J=9.0 Hz, J=0.9 Hz, H3), 4.91-4.84 (1H, 
m, CH), 3.13-3.05 (2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  170.3, 166.4, 157.6, 138.9, 
137.3, 133.5, 131.2, 131.0, 129.4, 128.6, 128.5, 126.8, 125.2, 122.9, 120.8, 119.7, 119.4, 
117.7, 55.6, 37.5. Anal. Calcd for C22H17Cl3N2O3 (463.74): C, 56.98; H, 3.69; N, 6.04. Found: 
C, 57.10; H, 3.955; N, 6.23. 
(R)-5-Chloro-N-(1-(3,4-dichlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-
hydroxybenzamide 9r. 
White solid; yield 34%; mp 238-240 °C. IR (KBr pellet): 3305, 1684, 1635, 1593, 1539, 
1476, 1385, 1289, 1233, 1133, 1030, 824, 699, 650, 534 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.00 (1H, bs, NH), 10.59 (1H, bs, OH), 9.10 (1H, d, J=7.5 Hz, NH), 7.98 (2H, m, H6, 
H2´), 7.58 (1H, d, J=8.8 Hz, H5´), 7.50 (1H, dd, J=8.8 Hz, J=2.4 Hz, H6´), 7.41 (1H, ddd, 
J=8.9 Hz, J=2.5 Hz, J=1.0 Hz, H4), 7.30-7.23 (4H, m, H2´´, H3´´, H4´´, H5´´, H6´´), 7.21-
7.12 (1H, m, H4´´), 6.95 (1H, dd, J=8.8 Hz, J=1.0 Hz, H3), 4.93-4.84 (1H, m, CH), 3.15-3.07 
(2H, m, CH2). 
13
C NMR (75 MHz, DMSO)  170.3, 166.4, 157.7, 138.9, 137.4, 133.5, 131.2, 
131.0, 129.4, 128.7, 128.5, 126.8, 125.1, 122.9, 120.8, 119.7, 119.4, 117.7, 55.6, 37.5. Anal. 
Calcd for C22H17Cl3N2O3 (463.74): C, 56.98; H, 3.69; N, 6.04. Found: C, 56.65; H, 3.255; N, 
6.355. 
(S)-4-Chloro-N-(1-(4-chlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9s. 
White solid; yield 64%; mp 223-225 °C. IR (KBr pellet): 3351, 3262, 1663, 1636, 1588, 
1539, 1491, 1401, 1340, 1297, 1219, 1094, 1013, 919, 852, 821, 773, 690, 573, 509 cm
-1
. 
1
H 
NMR (300 MHz, DMSO) 12.44 (1H, s, NH), 10.30 (1H, bs, OH), 9.03 (1H, d, J=6.9 Hz, 
NH), 8.00 (1H, dd, J=9.1 Hz, J=0.9 Hz, Ar), 7.65-7.62 (2H, m, AA´, BB´, H2´, H6´), 7.41-
7.32 (2H, m, AA´, BB´, H3´, H5´), 7.01-6.97 (2H, m, Ar), 4.68-4.60 (1H, m, CH), 1.44 (3H, 
d, J=6.9 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  171.2, 166.9, 159.9, 138.0, 137.8, 131.0, 
128.9, 127.2, 121.0, 119.3, 117.0, 115.4, 49.8, 18.3. Anal. Calcd for C16H14Cl2N2O3 (353.20): 
C, 54.41; H, 4.00; N, 7.93. Found: C, 54.81; H, 3.885; N, 7.955. 
(R)-4-Chloro-N-(1-(4-chlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9t. 
White solid; yield 73%; mp 226-227 °C. IR (KBr pellet): 3351, 3262, 1663, 1634, 1588, 
1538, 1491, 1400 1339, 1297, 1218, 1164, 1094, 1013, 919, 852, 821, 785, 773, 690, 573, 509 
cm
-1
. 
1
H NMR (300 MHz, DMSO) 12.44 (1H, s, NH), 10.30 (1H, bs, OH), 9.03 (1H, d, 
J=6.9 Hz, NH), 8.00 (1H, dd, J=10.2 Hz, J=1.2 Hz, Ar), 7.65-7.62 (2H, m, AA´, BB´, H2´, 
H6´), 7.37-7.35 (2H, m, AA´, BB´, H3´, H5´), 7.01-6.98 (2H, m, Ar), 4.68-4.59 (1H, m, CH), 
1.44 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  171.2, 166.9, 159.9, 138.0, 137.8, 
131.0, 128.9, 127.2, 121.0, 119.3, 117.0, 115.3, 49.8, 18.3. Anal. Calcd for C16H14Cl2N2O3 
(353.20): C, 54.41; H, 4.00; N, 7.93. Found: C, 54.245; H, 4.145; N, 7.955.(S)-4-Chloro-N-(1-
(4-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 9u. 
White solid; yield 69%; mp 203-205 °C. IR (KBr pellet): 3304, 2965, 1667, 1635, 1598, 
1531, 1492, 1403, 1300, 1238, 1092, 1014, 916, 824, 860, 824, 767, 678, 506 cm
-1
. 
1
H NMR 
  
52 
 
(300 MHz, DMSO) 12.24 (1H, s, NH), 10.38 (1H, bs, OH), 8. 85 (1H, d, J=8.3 Hz, NH), 
7.99 (1H, d, J=9.0 Hz, H6), 7.66-7.60 (2H, m, AA´, BB´, H2´, H6´), 7.38-7.32 (2H, m, AA´, 
BB´, H3´, H5´), 7.00-6.96 (2H, m, H3, H5), 4.53 (1H, t, J=7.6 Hz, CH), 2.22-2.11 (1H, m, 
CH), 0.96 (6H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  170.2, 166.1, 158.8, 137.8, 
137.4, 131.7, 128.9, 127.3, 121.1, 119.5, 116.9, 116.4, 59.2, 30.9, 19.4, 18.6. Anal. Calcd for 
C18H18Cl2N2O3 (381.25): C, 56.71; H, 4.76; N, 7.35. Found: C, 57.065; H, 5.07; N, 7.32. 
 
 
5-Chloro-N-(2-(3-chlorophenylamino)-2-oxoethyl)-2-hydroxybenzamide 9v. 
White solid; yield 32%; mp 244-245 °C. IR (KBr pellet): 3343, 3308, 1690, 1633, 1596, 
1538, 1483, 1431, 1285, 1270, 1221, 1198, 1120, 999, 974, 901, 870, 823, 776, 678, 535 cm
-1
. 
1
H NMR (300 MHz, DMSO) 12.19 (1H, s, NH), 10.32 (1H, bs, OH), 9.22 (1H, d, J=9.2 Hz, 
NH), 7.95 (1H, d, J=2.7 Hz, H6), 7.80 (1H, t, J=2.5 Hz, H2´), 7.45 (2H, dd, J=8.0 Hz, J=2.5 
Hz, H4´, H6´), 7.34 (1H, t, J=8.0 Hz, H5´), 7.11 (1H, dd, J=8.7 Hz, J=2.7 Hz, H4), 6.98 (1H, 
d, J=8.7 Hz, H3), 4.13 (2H, d, J=5.4 Hz, CH2). 
13
C NMR (75 MHz, DMSO)  167.7, 167.1, 
158.0, 140.4, 133.5, 33.3, 130.8, 128.4, 123.3, 122.8, 119.5, 118.8, 117.7, 117.6, 43.4. Anal. 
Calcd for C15H12Cl2N2O3 (339.17): C, 53.12; H, 3.57; N, 8.26. Found: C, 53.19; H, 3.775; N, 
8.17. 
(S)-5-Chloro-N-(1-(3-chlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9w. 
White solid; yield 43%; mp 222-224 °C. IR (KBr pellet): 3367, 3285, 3060, 1679, 1627, 
1578, 1598, 1483, 1413, 1363, 1280, 1235, 1212, 1115, 1077, 1047, 890, 826, 787, 779, 676, 
651, 598, 535 cm
-1
. 
1
H NMR (300 MHz, DMSO) 12.19 (1H, s, NH), 10.34 (1H, bs, OH), 
9.10 (1H, d, J=6.9 Hz, NH), 8.04 (1H, d, J=2.5 Hz, H6), 7.81 (1H, t, J=2.0 Hz, H2´), 7.50-
7.47 (1H, m, H6´), 7.44 (1H, dd, J=8.8 Hz, J=2.5 Hz, H4), 7.34 (1H, t, J=8.0 Hz, H5´), 7.15-
7.08 (1H, m, H4´), 6.96 (1H, d, J=8.8 Hz, H3), 4.69-4.55 (1H, m, CH), 1.44 (3H, d, J=7.2 Hz, 
CH3). 
13
C NMR (75 MHz, CDCl3)  171.4, 166.6, 158.0, 140.5, 133.5, 133.3, 130.7, 128.5, 
123.4, 122.8, 119.4, 119.0, 117.9, 117.5, 50.0, 18.2. Anal. Calcd for C16H14Cl2N2O3 (353.20): 
C, 54.41; H, 4.00; N, 7.93. Found: C, 54.00; H, 4.16; N, 7.965. 
(R)-5-Chloro-N-(1-(3-chlorophenylamino)-1-oxopropan-2-yl)-2-hydroxybenzamide 9x. 
White solid; yield 3%; mp 225-226 °C. IR (KBr pellet): 3368, 3285, 1679, 1627, 1598, 1579, 
1541, 1483, 1413, 1295, 1213, 1115, 890, 826, 787, 676, 535 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 12.21 (1H, s, NH), 10.35 (1H, bs, OH), 9.10 (1H, d, J=6.9 Hz, NH), 8.00 (1H, d, 
J=2.5 Hz, H6), 7.81 (1H, t, J=2.0 Hz, H2´), 7.52-7.46 (1H, m, H6´), 7.43 (1H, dd, J=8.8 Hz, 
J=2.5 Hz, H4), 7.34 (1H, t, J=8.0 Hz, H5´), 7.16-7.08 (1H, m, H4´), 6.98 (1H, d, J=8.8 Hz, 
H3), 4.71-4.55 (1H, m, CH), 1.45 (3H, d, J=7.2 Hz, CH3). 
13
C NMR (75 MHz, CDCl3)  
171.4, 166.6, 158.0, 140.5, 133.5, 133.3, 130.7, 128.4, 123.3, 122.9, 119.4, 119.1, 117.8, 
117.5, 50.0, 18.2. Anal. Calcd for C16H14Cl2N2O3 (353.20): C, 54.41; H, 4.00; N, 7.93. Found: 
C, 54.64; H, 4.10; N, 7.895. 
(S)-5-Chloro-N-(1-(3-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 
9y. 
White solid; yield 46%; mp 244-245 °C. IR (KBr pellet): 3282, 1660, 1632, 1595m, 1535, 
1481, 1418, 1375, 1355, 1279, 1251, 1200, 1170, 867, 822, 790, 771, 721, 649 cm
-1
.  
1
H NMR (300 MHz, DMSO) 12.01 (1H, s, NH), 10.44 (1H, bs, OH), 8.94 (1H, d, J=8.1 Hz, 
NH), 8.00 (1H, d, J=2.4 Hz, H6), 7.83 (1H, t, J=2.0 Hz, H2´), 7.48-7.41 (2H, m, H6´, H4´), 
7.33 (1H, t, J=8.1 Hz, H5´), 7.11 (1H, ddd, J=8.7 Hz, J=2.2 Hz, J=1.0 Hz, H4 ), 6.97 (1H, d, 
J=8.7 Hz, H3), 4.53 (1H, t, J=7.5 Hz, CH), 2.23-2.12 (1H, m, CH), 0.96 (6H, d, J=6.6 Hz, 
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CH3). 
13
C NMR (75 MHz, CDCl3)  170.4, 165.7, 156.9, 140.2, 133.3, 133.2, 130.7, 129.2, 
123.5, 123.1, 119.2, 119.0, 118.6, 117.9, 59.3, 30.9, 19.4, 18.6. Anal. Calcd for 
C18H18Cl2N2O3 (381.25): C, 56.71; H, 4.76; N, 7.35. Found: C, 57.105; H, 4.965; N, 7.245. 
(R)-5-Chloro-N-(1-(3-chlorophenylamino)-3-methyl-1-oxobutan-2-yl)-2-hydroxybenzamide 
9z. 
White solid; yield 39%; mp 211-212 °C. IR (KBr pellet): 3310, 2966, 1674, 1637, 1595, 
1542, 1482, 1426, 1292, 1212, 1099, 822, 779, 680, 651 cm
-1
. 
1
H NMR (300 MHz, DMSO) 
12.02 (1H, s, NH), 10.44 (1H, bs, OH), 8.94 (1H, d, J=8.1 Hz, NH), 8.00 (1H, d, J=2.2 Hz, 
H6), 7.83 (1H, t, J=2.0 Hz, H2´), 7.48-7.41 (2H, m, H6´, H4´), 7.34 (1H, t, J=7.6 Hz H5´), 
7.12 (1H, ddd, J=8.7 Hz, J=2.2 Hz, J=1.2 Hz, H4 ), 6.98 (1H, d, J=9.0 Hz, H3), 4.53 (1H, t, 
J=7.5 Hz, CH), 2.23-2.11 (1H, m, CH), 0.96 (6H, d, J=6.6 Hz, CH3). 
13
C NMR (75 MHz, 
CDCl3)  170.4, 165.7, 156.9, 140.2, 133.3, 133.2, 130.7, 129.2, 123.5, 123.1, 119.2, 119.0, 
118.6, 117.9, 59.3, 30.9, 19.4, 18.6. Anal. Calcd for C18H18Cl2N2O3 (381.25): C, 56.71; H, 
4.76; N, 7.35. Found: C, 56.35; H, 4.925; N, 7.215. 
(S)-5-Chloro-N-(1-(3-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9aa. 
White solid; yield 60%; mp 181-183 °C. IR (KBr pellet): 3297, 1672, 1633, 1594, 1536, 
1483, 1416, 1288, 1236, 1180, 865, 823, 746, 693, 675, 535 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 12.03 (1H, bs, NH), 10.45 (1H, bs, OH), 9.09 (1H, d, J=7.4 Hz, NH), 7.97 (1H, d, 
J=2.5 Hz, H6), 7.79 (1H, t, J=1.9 Hz, H2´), 7.49-7.09 (9H, m, H4, H4´, H5´, H6´, H2´´, H3´´, 
H4´´, H5´´, H6´´), 6.94 (1H, d, J=8.8 Hz, H3), 4.95-4.81 (1H, m, CH), 3.24-3.03 (2H, m, 
CH2). 
13
C NMR (75 MHz, DMSO)  170.1, 166.4, 157.6, 140.3, 137.4, 133.5, 133.3, 130.7, 
129.4, 128.6, 128.5, 126.8, 123.5, 122.9, 119.4, 119.1, 118.0, 117.7, 55.6, 37.5. Anal. Calcd 
for C22H18Cl2N2O3 (429.30): C, 61.55; H, 4.23; N, 6.53. Found: C, 61.735; H, 4.33; N, 6.595. 
(R)-5-Chloro-N-(1-(3-chlorophenylamino)-1-oxo-3-phenylpropan-2-yl)-2-hydroxybenzamide 
9bb. 
White solid; yield 7.5%; mp 182-184 °C. IR (KBr pellet): 3305, 1672, 1636, 1595, 1537, 
1483, 1426, 1418, 1289, 1230, 1101, 824, 778, 699, 680, 650, 535 cm
-1
. 
1
H NMR (300 MHz, 
DMSO) 12.03 (1H, bs, NH), 10.50 (1H, bs, OH), 9.09 (1H, d, J=7.4 Hz, NH), 7.97 (1H, d, 
J=2.7 Hz, H6), 7.79 (1H, t, J=2.1 Hz, H2´), 7.47-7.11 (9H, m, H4, H4´, H5´, H6´, H2´´, H3´´, 
H4´´, H5´´, H6´´), 6.93 (1H, d, J=8.7 Hz, H3), 4.93-4.85 (1H, m, CH), 3.22-3.05 (2H, m, 
CH2). 
13
C NMR (75 MHz, DMSO)  13C NMR (75 MHz, DMSO)  170.1, 166.4, 157.6, 
140.3, 137.4, 133.5, 133.3, 130.7, 129.4, 128.6, 128.5, 126.8, 123.5, 122.9, 119.4, 119.1, 
118.0, 117.7, 55.6, 37.5. Anal. Calcd for C22H18Cl2N2O3 (429.30): C, 61.55; H, 4.23; N, 6.53. 
Found: C, 61.31; H, 4.32; N, 6.475. 
 
5.2. Study of the mechanism of the rearrangement: imidazolinone intermediate 
formation (Paper VI). 
With the aim of elucidating the mechanism of the rearrangement and study its extension, 
several experiments were performed.  
It was proved that the rearrangement occurs as well with salicylanilides without any 
substituent on both rings – salicylic and aniline or with electron activating methyl and 
methoxy group on aniline moiety. Furthermore, it is not limited only for salicylanilide esters 
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of Cbz protected AA. We have used tert-butyloxycarbonyl (Boc) protected Val and Leuch 
anhydride of Phe 154 for esterification and the appropriate SAL esters gave after N-
deprotection the rearranged diamides which were isolated and characterized. 
In a previous publication 154 it was proposed a possible mechanism for this rearrangement 
where the deprotected amino group immediately attacks the carbonyl of amide and forms a 
cyclic seven-membered ester which is opened by the action of the released aniline to produce 
diamide (Scheme 15) . In order to confirm the above-proposed mechanism, a large number of 
experiments were performed where activated anilines bearing a stronger nucleophilic 
substituent in the position 4, were added to the reaction mixture. None of the recombinant 
diamides was isolated, only the product with the original aniline moiety 9. Therefore, an 
alternative mechanism involving the reorganization of the molecule without liberation of 
aniline moiety was investigated.  
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Scheme 15.  First proposed mechanism for the rearrangement. 
 
We hypothesised that the free amino group attacks the amidic carbonyl and amidic nitrogen 
attacks the ester carbonyl to generate the bicyclic intermediate 7 which is spontaneously 
transformed into a five-membered hydroxyimidazolinone 11 which opens under formation of 
diamide 9 (Scheme 16). 
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Scheme 16. Second proposed mechanism for the rearrangement. 
 
Support for a five-membered imidazoline ring as an intermediate in this rearrangement came 
from our experimental results. During the purification by column chromatography of the 
corresponding diamide 9a, we isolated a side-product that resulted to be a dehydrated form of 
this five-membered ring intermediate as a racemic mixture, 2-(5-chloro-2-hydroxyphenyl)-1-
(3-chlorophenyl)-4-isopropyl-1H-imidazol-5(4H)-one 11a (Figure 25). The structure of 11a 
was confirmed by MS, IR, 2D NMR and the X-ray study. The same type of substituted 1H-
imidazol-5(4H)-one was isolated during the purification of 9b, 4-benzyl-2-(5-chloro-2-
hydroxyphenyl)-1-(3-chlorophenyl)-1H-imidazol-5(4H)-one 11b (Figure 25) and determined 
by IR, 
1
H NMR and 
13
C NMR. 
 
OH
OH
HN
N
O
R3
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11  
Figure 25. Isolated dehydrated reaction intermediates. 
 
Additional structure determination of 2-(5-chloro-2-hydroxyphenyl)-1-(3-chlorophenyl)-4-
isopropyl-1H-imidazol-5(4H)-one 9a was made by 
1
H NMR, 
13
C NMR 
15
N NMR in 2D 
experiments (gradient-selected (gs)-COSY, gs-HMQC, gs-HMBC) as well as by the 
construction of the computer model using a DFT method (B3LYP/6-31G(d)). Based on this 
model was calculated IR and 
1
H and 
13
C NMR spectra. Finally, the compound 11a was also 
studied by X-ray diffraction techniques (Figure 26). 
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Figure 26. The ORTEP view of the compound 11a. 
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6. Conclusions. 
The outcomes of the literary research that summarizes all main kinds of prodrug 
modifications of phenolic-containing drugs is summarised in a review-article (paper I) which 
was sent for publication after its abstract acceptance to Pharmaceutical Drug Design journal.  
The main scope of the thesis is summarised in the enclosed articles II, III and V. The results 
obtained in this study show that although N-Cbz-AA esters of SAL showed high 
antimycobacterial activity against all tested mycobacterial strains, their limited stability 
compared with the later synthesised carbamate ester of SAL make them not so interesting 
candidates. 
The derivatization of the phenolic group of SAL in the form of carbamate appears to be the 
most useful approach, increasing the antimycobacterial activity and pharmacokinetic 
properties of SAL. Whether this is a simple effect of an increased hydrophobicity and 
therefore better permeability through the lipophilic mycobacterial cell wall or a direct effect 
of the carbamate moiety remains to be elucidated.  
However, the high potencies of these newly prepared compounds, particularly those against 
the MDR-TB strains, together with their favourable selectivity and the stability in acidic 
environment which converts these compounds in good candidates for oral administration 
makes these SAL-derived carbamates promising drug candidates which will be further 
investigated. 
In the course of our research, unexpected benzoxazepine-diones were formed. Unluckily, 
these compounds did not report any antitubercular activity. The unexpected formation of 
novel seven membered rings is reported in the enclosed paper IV. 
The deprotection of the synthesized N-Cbz-AA esters yielded an unexpected product later 
identified  as hydroxy-N-(phenylamino)-oxo-alkyl)benzamides. Although these compounds 
show some activity, an important decrease of the activity was observed compared with the 
starting SAL or the corresponding N-Cbz-AA ester derivatives. The report of this study is 
now being prepared for publication. The mechanism of this rearrangement was elucidated and 
its extension proved by the performance of several experiments. All this results were recently 
reported and enclosed as paper VI. 
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